

chain nodes :
6 12 15 17 24 25 27 28 29
ring nodes :
1 2 3 4 5 7 8 9 10 11 18 19 20 21 22 23
chain bonds :
4-6 6-7 9-12 10-15 17-27 18-29 22-25 23-24 27-28 28-29
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 18-23 18-19 19-20 20-21 21-22
22-23
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-27 18-23
18-19 18-29 19-20 20-21 21-22 22-23 22-25 23-24 27-28 28-29
exact bonds :
6-7

G1:Ph,Cy

G2:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Ph,Cy
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10671326amendG.str



chain nodes :
6 12 15 17 18 25 26
ring nodes :
1 2 3 4 5 7 8 9 10 11 19 20 21 22 23 24

chain bonds :
4-6 6-7 9-12 10-15 17-18 18-19 23-26 24-25
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 19-20 19-24 20-21 21-22 22-23 23-24
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-18 18-19 19-20 19-24 20-21 21-22 22-23 23-24 23-26 24-25
exact bonds :
6-7

G1:Ph,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 15:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10671326amend2.str





chain nodes :
6 12 15
ring nodes :
1 2 3 4 5 7 8 9 10 11
chain bonds :
4-6 6-7 9-12 10-15
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15
exact bonds :
6-7

G1:Ph,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 15:CLASS

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:51:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:51:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      119 TO ITERATE

100.0% PROCESSED      119 ITERATIONS                          24 ANSWERS
SEARCH TIME: 00.00.01

L5           24 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 10:51:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        5 TO ITERATE

100.0% PROCESSED        5 ITERATIONS                           4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               4 TO      200

L6            4 SEA SSS SAM L2

=> s l2 full
FULL SEARCH INITIATED 10:51:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      121 TO ITERATE

100.0% PROCESSED      121 ITERATIONS                          76 ANSWERS
SEARCH TIME: 00.00.01

L7           76 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 10:51:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       41 TO ITERATE

100.0% PROCESSED       41 ITERATIONS                          38 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          436 TO     1204
PROJECTED ANSWERS:             391 TO     1129

L8           38 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 10:51:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      861 TO ITERATE

100.0% PROCESSED      861 ITERATIONS                         831 ANSWERS
SEARCH TIME: 00.00.01
```

```
L9          831 SEA SSS FUL L3

=> fil hcaplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                           484.85     485.06

FILE 'HCAPLUS' ENTERED AT 10:52:02 ON 29 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Nov 2005  VOL 143 ISS 23
FILE LAST UPDATED: 28 Nov 2005  (20051128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l5
L10           1 L5

=> d ed abs ibib hitstr
```

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Apr 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I [A = C, C(:O), N (with proviso, that at least one A = C); B = O, NR2, S(O)t, C(:O), C(:S), C(:NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)tR4, CHO, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(:O)NR3R3, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional hetercyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTs, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004:292029 HCAPLUS
DOCUMENT NUMBER: 140:321158
TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents
INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Mcconnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005197334 A1 20050908 US 2003-671326 20030925
CA 2500158 AA 20040408 CA 2003-2500158 20030926
EP 1543017 A2 20050622 EP 2003-770506 20030926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-414207P P 20020926
US 2003-448216P P 20030219
WO 2003-US30478 W 20030925
OTHER SOURCE(S): MARPAT 140:321158
IT 677726-85-1P 677726-86-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and hydrolysis of; preparation of bifunctional heterocyclic compds.
for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-85-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



540/454

PAGE 1-B



RN 677726-86-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



540/454

IT 677726-16-8P 677726-18-0P 677726-28-2P 514/

677726-77-1P 677726-78-2P 677726-79-3P
677726-80-6P 677726-82-8P 677726-87-3P
677726-88-4P 677726-78-5P 677727-79-6P
677727-80-9P 677727-81-0P 677727-82-1P
677727-83-2P 677727-90-1P 677727-92-3P
677726-95-6P 677727-96-7P 677727-97-8P
677727-99-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-16-8 HCAPLUS
CN Erythromycin, N-demethyl-N-[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

544/137

514/236.2

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 677726-18-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-28-2 HCAPLUS
CN Erythromycin, N-[3-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 677726-77-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[4-[1-[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-78-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-79-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-80-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[4-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-82-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-87-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-(3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-88-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677727-78-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[3-[1-[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677727-79-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-80-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-81-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-82-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-83-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-90-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-92-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-95-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-96-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-97-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-99-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



```
=> s l7
L11           1 L7

=> d ed abs ibib hitstr
```

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Apr 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I [A = C, C(:O), N (with proviso, that at least one A = C); B = O, NR2, S(O)r, C(:O), C(:S), C(:NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)rR4, CHO, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(:O)NR3R3, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional hetercyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTs, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004:292029 HCAPLUS
DOCUMENT NUMBER: 140:321158
TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents
INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Mcconnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005197334	A1	20050908	US 2003-671326	20030925
CA 2500158	AA	20040408	CA 2003-2500158	20030926
EP 1543017	A2	20050622	EP 2003-770506	20030926

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:		US 2002-414207P	P 20020926
		US 2003-448216P	P 20030219
		WO 2003-US30478	W 20030925

OTHER SOURCE(S): MARPAT 140:321158

IT 677726-15-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and N-dealkylation of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-15-7 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



IT 677726-17-9P 677726-31-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and hydrolysis of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-17-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-31-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



IT 677726-16-8P 677726-18-0P 677726-26-0P
677726-27-1P 677726-28-2P 677726-29-3P
677726-30-6P 677726-33-9P 677726-34-0P
677726-35-1P 677726-36-2P 677726-46-4P
677726-47-5P 677726-48-6P 677726-49-7P
677726-50-0P 677726-51-1P 677726-52-2P
677726-53-3P 677726-54-4P 677726-55-5P
677726-57-7P 677726-58-8P 677726-60-2P
677726-62-4P 677726-63-5P 677726-65-7P
677726-66-8P 677726-68-0P 677726-70-4P
677726-72-6P 677726-73-7P 677726-74-8P
677726-75-9P 677726-76-0P 677726-77-1P
677726-78-2P 677726-79-3P 677726-80-6P
677726-81-7P 677726-82-8P 677726-83-9P
677726-84-0P 677726-89-5P 677726-90-8P
677727-77-4P 677727-78-5P 677727-79-6P
677727-80-9P 677727-81-0P 677727-82-1P
677727-83-2P 677727-84-3P 677727-85-4P
677727-86-5P 677727-87-6P 677727-88-7P
677727-89-8P 677727-90-1P 677727-91-2P
677727-92-3P 677727-93-4P 677727-94-5P
677727-95-6P 677727-98-9P 677727-99-0P
677728-00-6P 677728-01-7P 677728-02-8P

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
677728-03-9P 677728-04-0P 677729-42-9P
678182-71-3DP, trans-cyclohexanol isomers
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-16-8 HCAPLUS
CN Erythromycin, N-demethyl-N-[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 677726-18-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 677726-26-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-27-1 HCAPLUS
CN Erythromycin, N-[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 677726-28-2 HCAPLUS
CN Erythromycin, N-[3-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

PAGE 2-A



RN 677726-29-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-30-6 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-33-9 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-34-0 HCAPLUS
CN Erythromycin, N-[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-36-2 HCAPLUS
CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-35-1 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 677726-46-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-47-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-48-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-49-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[4-[[2-(acetyloxy)ethyl]methylamino]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-50-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-51-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-(3-pyridinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-52-2 HCAPLUS
CN Erythromycin, N,N-didemethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 677726-53-3 HCAPLUS
CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-54-4 HCAPLUS
CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-55-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-57-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-58-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4'-cyano-2-fluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-60-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-62-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-63-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4-cyano-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-65-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-66-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-3-[4-[[(methylsulfonyl)amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-68-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[3-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-70-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-72-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[[[(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-73-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-74-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-75-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-76-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B

RN 677726-77-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[4-[1-[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-78-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-79-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-80-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[4-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-81-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-82-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-83-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 677726-84-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-89-5 HCAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-90-8 HCAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677727-77-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677727-78-5 HCAPLUS

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[3-[1-[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677727-79-6 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-80-9 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-81-0 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-82-1 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-83-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-84-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(2-fluoro-4-methylphenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-85-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-86-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(4-fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-87-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(3-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-88-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(2-hydroxyethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-89-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-90-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-91-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-92-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-93-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[2-fluoro-4'-[[(4-quinolinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-94-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-95-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-98-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-99-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-00-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(3-chloro-4-methoxyphenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-01-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-cyclopentyl-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-02-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-[4-(trifluoromethoxy)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-03-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-[4-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-04-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluoro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677729-42-9 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 678182-71-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(trans-4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,

```
=> s l9
L12          41 L9

=> d ed abs ibib hitstr 1-41
```

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Sep 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides macrocyclic azithromycin compds. I and II, wherein T is macrolide; R1 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl ester, amide,thio-acyl, thio-ester, amine; R2 is H, alkoxy; D is single bond, alkyl, alkenyl,alkynyl, acyl, ester, amide, imine, sulfonyl, amine, thio-acyl, thio-amide; E is aromatic heterocycle, carbocycle, CO, CO, amide, imine; F is single bond, alkyl,alkenyl, alkynyl; G is aryl, heteroaryl, biaryl, bicyclic, tricyclic, aryl, were prepared as antibacterial, anti-proliferative, prokinetic, and antiinflammatory agents. Thus, III was prepared and used as antibacterial, anti-proliferative, and antiinflammatory agent.

ACCESSION NUMBER: 2005:1004760 HCAPLUS
DOCUMENT NUMBER: 143:306499
TITLE: Preparation of macrocyclic azithromycin compounds as antibacterial, anti-proliferative, and antiinflammatory agents
INVENTOR(S): Farmer, Jay J.; Bhattacharjee, Ashoke; Chen, Yi; Goldberg, Joel A.; Ippolito, Joseph A.; Kanyo, Zoltan F.; Lou, Rongliang; Oyelere, Adegboyega K.; Sherer, Edward C.; Sutcliffe, Joyce A.; Wang, Deping; Wu, Yusheng; Du, Yanming
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085266	A2	20050915	WO 2005-US6082	20050225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-548280P P 20040227
US 2004-575949P P 20040601

IT 864529-35-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

F

PAGE 2-A

PAGE 2-B



IT 864529-57-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)
RN 864529-57-7 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(methylsulfonyl)oxy]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 864529-35-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Sep 2005
GI



I



II

AB Amidoxime and amidine oxazolidinones I [wherein X = certain O-containing five-membered heterocycle; W = CH2OH, CH2NHAc, etc.; Y1 - Y3 = CH, N, N(O) or CF; G = CH2, etc.; U = CH2, CF2, O, S, SO or SO2; R2 = H or alkyl; V = N or C; Z = H, OH, alkoxy, etc., or pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. For instance, II, which showed antibacterial activity with MIC values of 1-4 μg/mL against S. aureus, S.pyogenes and S. pneumoniae, was synthesized from Me bromoacetate and 2-amino-5-nitrophenol in eight steps. The invented compds. are potentially useful for the treatment of bacteria infectious diseases.

ACCESSION NUMBER: 2005:979647 HCAPLUS
DOCUMENT NUMBER: 143:286413
TITLE: Preparation of oxazolidinone compounds as antibacterial agents
INVENTOR(S): Gordeev, Mikhail Fedorovich; Jain, Rama; Josyula, Vara Prasad Venkata Nagendra; Luehr, Gary Wayne
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082897	A1	20050909	WO 2005-IB102	20050117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PRIORITY APPLN. INFO.: US 2004-540214P P 20040128
IT 864073-59-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxazolidinones as antibacterial agents)
RN 864073-59-6 HCAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-methyl-7-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 3-(O-methyloxime) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Jul 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, etc.; M = (un)substituted alkyl, alkenyl, alkynyl; X = O, -N(O)-, -O-N=, etc.; L = (un)substituted alkyl, alkenyl, alkynyl; R1 = halo, CF3, NO2, etc.; R2 = CN, halo, CF3, etc.; R3 = OR4, NR4R4, C(O)R4, etc.; R4 = H, alkyl, alkenyl, etc.; m = 0-4; n = 0-4] and their pharmaceutically acceptable salts, are prepared and disclosed as antiinflammatory agents. Thus, e.g., II was prepared by alkylation of amine III (preparation given) with 3-bromo-1,1,1-trifluoro-2-propanol. The activity of I was evaluated using surface binding studies and fluorescence polarization (no data). I should prove useful as antiinflammatory agents. Pharmaceutical compns. comprising I are disclosed.

ACCESSION NUMBER: 2005:588915 HCAPLUS
DOCUMENT NUMBER: 143:97346
TITLE: Preparation of halogenated biaryl oxazolidinones as antiinflammatory agents
INVENTOR(S): Chen, Shili; Zhou, Jiacheng; Wu, Yunsheng; Wang, Deping; Salvino, Joseph M.; Oyelere, Adegboyega K.; Lou, Rongliang
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA; Bhattacharjee, Ashoke; Chen, Yi
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061468	A1	20050707	WO 2004-US39988	20041201
WO 2005061468	C1	20050909		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005153971	A1	20050714	US 2004-1446	20041201

PRIORITY APPLN. INFO.: US 2003-530371P P 20031217
US 2004-576267P P 20040602

OTHER SOURCE(S): MARPAT 143:97346
IT 856907-04-5P 856907-43-2P 856907-81-8P
856907-85-2P 856907-86-3P 856907-87-4P
856907-88-5P 856907-89-6P 856907-92-1P
856907-97-6P 856907-98-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of halogenated biaryl oxazolidinones as antiinflammatory

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
agents)
RN 856907-04-5 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-43-2 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoro-2-hydroxypropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-81-8 HCAPLUS

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-methyl-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-85-2 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 856907-86-3 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-87-4 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-[[4-(hydroxymethyl)-5-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 856907-88-5 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-[[5-(hydroxymethyl)-4-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-89-6 HCAPLUS
CN 2-Oxazolidinone, 5-[[4,5-bis(methoxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-92-1 HCAPLUS
CN Acetamide, N-[[1-[[(5R)-3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 856907-97-6 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-98-7 HCAPLUS
CN 2-Oxazolidinone, 5-[[5-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[2-fluoro-4'-[[(3-fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-95-3P 847490-64-6P 847490-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of halogenated biaryl oxazolidinones as antiinflammatory agents)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-64-6 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 847490-65-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Jun 2005
GI



AB Title compds. I [X = C, N; R1-1' = H, F; R2 = amino, alkoxy, triazolyl, etc.; R3-4 = H, alkyl, etc.; Het = heterocyclic ring, heteroarom. ring, etc.] are prepared For instance, (R)-3-[4-[2-(2-methyltetrazol-5-yl)pyridin-5-yl]-3-fluorophenyl]-5-hydroxymethyloxazolidin-2-one (II) is prepared from 2-(2-methyltetrazol-5-yl)-5-bromopyridine and (R)-3-(4-tributylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol (preparation given). II exhibits MIC50 = 0.5 μg/mL against MRSA and 0.25 μg/mL against VRE. I show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The amino acid or phosphate prodrugs of the invention show good water solubility Further, the derivs. of the present invention may exert potent antibacterial activity vs. various human and animal pathogens, including Gram-pos. bacteria such as Staphylococci, Enterococci and Streptococci, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium.

ACCESSION NUMBER: 2005:564663 HCAPLUS
DOCUMENT NUMBER: 143:97343
TITLE: Preparation of oxazolidinone broad-spectrum antibiotics
INVENTOR(S): Rhee, Jae Keol; Im, Weon Bin; Cho, Chong Hwang; Choi, Sung Hak; Lee, Tae Ho
PATENT ASSIGNEE(S): Dong-A Pharm.Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058886	A1	20050630	WO 2004-KR3327	20041217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: KR 2003-93342 A 20031218
KR 2004-58809 A 20040727

OTHER SOURCE(S): MARPAT 143:97343
IT 700370-32-7P 831201-38-8P 856866-76-7P 856866-77-8P 856867-06-6P 856867-08-8P

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)
RN 700370-32-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-38-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856866-76-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 856866-77-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856867-06-6 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[4-(hydroxymethyl)-2-thiazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)

RN 856867-07-7 HCAPLUS
CN Glycine, [2-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 856867-08-8 HCAPLUS
CN Glycine, [2-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856867-07-7
CMF C24 H21 F N6 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 856867-07-7

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Jun 2005
GI



I



II

AB The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivs. (shown as I; variables defined below; e.g. (S)-N-[[3-[4-(4-cyanomethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide (shown as II)), processes for making compds. as well as antimicrobial compns. containing said derivs. as active ingredients and methods of treating bacterial infections with the said derivs. MIC (μg/mL) and/or ED50 (mg/kg) values are tabulated for 5 types of bacteria. For I: m = 0-1 and n = 1-3; X = -CN, -OH, or halogen; Y = H (with the proviso that when Y is H, X is OH, F or CN), (un)substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heterocyclylamino, heterocyclylcarbonyl, cyano, halogen, (un)substituted amino, (un)substituted hydrazino; or X and Y together form a 3-membered carbocyclic ring or heterocyclic ring containing a hetero atom = O or S or X and Y together form an (un)substituted, (un)saturated 3 to 7 membered heterocyclic ring having 1-4 hetero atoms = N, O, S or includes the S atom of groups like sulfinyl or sulfonyl as a part of heterocyclic ring or X and Y together form O:. A, B = H, C1-C6 alkyl, or halogen; R2, R3 = H or halogen. R4 = C1-C6 alkylsulfonyloxy, alkylsulfonyloxyacetamido, (un)substituted aminosulfonyloxy, alkyloxysulfonyloxy, arylsulfonyloxy, (un)substituted amino, azido, aminonitrilo, isocyanato, formamido, N-hydroxyformamido, substituted C1-C6 alkanoyloxy, (un)substituted C1-C6 alkylamido, (un)substituted C1-C6 alkylthiocarbonylamido, C1-C6 alkylsulfonamido; substituted arylsulfonamido, (un)substituted alkylcarbamato, (un)substituted ureido, (un)substituted five to six membered heterocyclyl ring, (un)substituted five to six membered heteroaryl ring, (un)substituted heteroaryloxy, (un)substituted heteroarylamino, or mercapto substituted by C1-C6 alkyl group; addnl. details including provisos are given in the claims. Methods of preparation are claimed and .apprx.180 example prepns. are included. For example, 51 % II was prepared by reacting (S)-N-[[3-[4-(1-oxa-6-azaspiro[2.5]octan-6-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide with KCN in MeOH/DMF (1:5) at 25° for 14 h.

ACCESSION NUMBER: 2005:523447 HCAPLUS
DOCUMENT NUMBER: 143:59964
TITLE: Preparation of 3-(4-piperidinophenyl)oxazolidinones

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
having antibacterial activity with improved in vivo efficacy
INVENTOR(S): Deshpande, Prasad Keshav; Sindkhedkar, Milind Dattatraya; Phansalkar, Mahesh Shriram; Yeole, Ravindra Dattatrya; Gupta, Shrikant Vinayak; Chugh, Yati; Shetty, Nitin; Bhagwat, Sachin Subhash; De Souza, Noel John; Patel, Mahesh Vithalbhai
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054234	A2	20050616	WO 2004-IN276	20040908
WO 2005054234	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005143421	A1	20050630	US 2004-935708	20040907
PRIORITY APPLN. INFO.:			IN 2003-MU924 A	20030908
OTHER SOURCE(S):		MARPAT 143:59964		

IT 853797-09-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)
RN 853797-09-8 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 853797-04-3P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-4-carboethoxy-1,2,3-triazole
853797-06-5P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-4-aminocarbonyl-1,2,3-triazole
853797-08-7P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-4-cyano-1,2,3-triazole
853797-10-1P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-carboethoxy-1,2,3-triazole
853797-11-2P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-aminocarbonyl-1,2,3-triazole
853797-12-3P, (S)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-cyano-1,2,3-triazole
853797-45-2P, (R)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-4-cyano-1,2,3-triazole
853797-46-3P, (R)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-carboethoxy-1,2,3-triazole
853797-47-4P, (R)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-aminocarbonyl-1,2,3-triazole
853797-48-5P, (R)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-5-cyano-1,2,3-triazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)
RN 853797-04-3 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-06-5 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 853797-08-7 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-10-1 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-11-2 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxamide, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 853797-12-3 HCAPLUS
CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-45-2 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-46-3 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 853797-47-4 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxamide, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-48-5 HCAPLUS
CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 853797-07-6, (R)-1-[[3-[4-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]-4-carboethoxy-1,2,3-triazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)
RN 853797-07-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-,

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 01 Jun 2005
AB A new series of N-linked 5-triazolylmethyl oxazolidinones with varying substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates. Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms. One of the compds. showed enhanced antibacterial activity against Moraxella catarrhalis.
ACCESSION NUMBER: 2005:465012 HCAPLUS
DOCUMENT NUMBER: 143:149749
TITLE: Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones
AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait
SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(12), 4113-4123
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 371195-29-8P
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)
RN 371195-29-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-41-3P 859445-42-4P 859445-43-5P
859445-44-6P 859445-45-7P 859445-46-8P
859445-47-9P 859445-48-0P 859445-49-1P
859445-50-4P 859445-51-5P 859445-52-6P
859445-53-7P 859445-54-8P 859445-55-9P
859445-56-0P

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)
RN 859445-41-3 HCAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-42-4 HCAPLUS
CN Piperazine, 1-acetyl-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-43-5 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 859445-44-6 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trichloroacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-45-7 HCAPLUS
CN Piperazine, 1-(dichloroacetyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-48-0 HCAPLUS
CN Piperazine, 1-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-49-1 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-46-8 HCAPLUS
CN 1-Piperazinecarbothioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-47-9 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-50-4 HCAPLUS
CN 1-Piperazinecarbothioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-51-5 HCAPLUS
CN Piperazine, 1-(1,2-dioxopropyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-52-6 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-53-7 HCAPLUS
CN Piperazine, 1-(cyclopentylcarbonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 859445-55-9 HCAPLUS
CN Piperazine, 1-benzoyl-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-56-0 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-40-2P
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antibacterial activity of new N-linked 5-triazolylmethyl

L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 859445-54-8 HCAPLUS
CN Piperazine, 1-(cyclohexylcarbonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolidinones)

RN 859445-40-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 371195-30-1
CMF C16 H19 F N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 May 2005
GI



I



II



III

AB The invention relates to a preparation of novel oxazolidinone derivs. of formula I (R is H, amide, aldehyde, or nitrile, etc.; each X is independently N or CH), useful as antibacterial agents. For instance, oxazolidinone derivative II [MIC (μg/mL): str. pyogenes 77A - 0.4, s. aureus 285 - 0.8, MRSA 2 - 1.6; LD50 >5000 mg/kg] was prepared via 1,3-dipolar cycloaddn. of vinyl acetate to (azidomethyl)oxazolidinone derivative III with a yield of 74%.

ACCESSION NUMBER: 2005:409511 HCAPLUS
DOCUMENT NUMBER: 142:463731
TITLE: A preparation of novel oxazolidinone derivatives, useful as antibacterial agents
INVENTOR(S): Kang, Jae-Hoon; Park, Chun-Ho; Kwon, Jin-Sun
PATENT ASSIGNEE(S): Il-Dong Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042523	A1	20050512	WO 2004-KR2805	20041103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: KR 2003-77372 A 20031103
KR 2004-82328 A 20041014

OTHER SOURCE(S): MARPAT 142:463731

IT **851529-76-5P 851529-81-2P 851529-82-3P**
851529-83-4P 851529-97-0P 851529-98-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-76-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-81-2 HCAPLUS
CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-82-3 HCAPLUS
CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 3-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Double bond geometry unknown.



RN 851529-83-4 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-97-0 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-98-1 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **851530-02-4P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851530-02-4 HCAPLUS
CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **851529-77-6P 851529-96-9P 851530-00-2P**
851530-01-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-77-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 851529-96-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851530-00-2 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851530-01-3 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 851529-78-7P 851529-85-6P 851529-86-7P
851529-87-8P 851529-88-9P 851529-89-0P
851529-90-3P 851529-91-4P 851529-92-5P
851529-93-6P 851529-94-7P 851529-95-8P
851529-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-78-7 HCAPLUS
CN Carbamic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-85-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 851529-86-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-tetrazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-87-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 851529-88-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 851529-89-0 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 851529-90-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-76-5
CMF C16 H18 F N5 O2

Absolute stereochemistry.



L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 851529-91-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-77-6
CMF C16 H14 F N5 O2

Absolute stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 851529-92-5 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 851529-83-4
CMF C17 H13 F N6 O2

Absolute stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 851529-93-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-76-5
CMF C16 H18 F N5 O2

Absolute stereochemistry.



CM 2

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 77-92-9
CMF C6 H8 O7



RN 851529-94-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-77-6
CMF C16 H14 F N5 O2

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 851529-95-8 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-83-4
CMF C17 H13 F N6 O2

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 851529-99-2 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-80-1P 851529-84-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)
RN 851529-80-1 HCAPLUS
CN 2-Oxazolidinone, 3-(4-amino-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 851529-84-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-azido-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Mar 2005
GI



I



II

AB Title compds. represented by the formula I [wherein A = isoxazolin-3,5-diyl, 2-oxazolinone-3,5-diyl, 2-furanone-3,5-diyl, 5-isoxazolinone-2,4-diyl; X = N or C; Z = oxy-isoxazolyl, (oxy)-1,2,3-triazolyl, aminocarbonylmethyl, etc.; R2-R5 = independently H, Cl, F, Me, NH2, or OH; L, Y = independently H, OH, F, O, NOH, NOalkyl; m, n, p = independently 0 or 1; and pharmaceutically acceptable salts thereof] were prepared as antimicrobial agents. For example, II was given in a multi-step synthesis starting from the reaction of 1,2,3,6-tetrahydropyridine with 3,4-difluoronitrobenzene. I were tested for inhibition against SAUR 9213, SPNE 9912, HINF 30063 and MC 30603 with MIC values of 0.25-64 μg/mL. Thus, I and their pharmaceutical compns. are useful as antibacterial agents for the treatment of a gram-neg. microbial infection.

ACCESSION NUMBER: 2005:182660 HCAPLUS
DOCUMENT NUMBER: 142:280197
TITLE: Preparation of aryloxazolidinone derivatives as antimicrobial agents
INVENTOR(S): Gordeev, Mikhail; Wang, Qiang
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019214	A1	20050303	WO 2004-IB2669	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005065187	A1	20050324	US 2004-924752	20040824
PRIORITY APPLN. INFO.:			US 2003-497531P	P 20030825

OTHER SOURCE(S): MARPAT 142:280197

IT 847256-81-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryloxazolidinone derivs. as antimicrobial agents)
RN 847256-81-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(3S,4R)-3,4-dihydroxy-1-piperidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847256-82-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazolidinone derivs. as antimicrobial agents)
RN 847256-82-0 HCAPLUS
CN 4-Piperidinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 847257-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxazolidinone derivs. as antimicrobial agents)
RN 847257-18-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1(2H)-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Mar 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl; R1 and R2 = independently = halo, CF3, CN, NO2, NR42, COR4, etc.; R3 = OR4, NR42, COR4, CO2R4, CSR4, etc.; R4 independently = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; M = (un)substituted, (un)saturated carbocycle or aryl heterocycle containing one or more heteroatoms chosen from N, O, and S; L = X, L1, L1X, XL2, L1XL2, XL1XL2, L1XL2X, X2, L1X2, X2L2, L1X2L2 wherein X independently = O, NR4, NO, N(OR4), NR4NR4, etc., and L1 and L2 are independently = (un)substituted-alkyl, -alkenyl, -alkynyl; m = 0-4; n = 0-4], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by conversion of TBDPS protected 1-bromo-4-(2-hydroxyethyl)benzene to the arylboronic acid which is coupled with N-[3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl]acetamide followed by desilylation, mesylation, and substitution with imidazole. I are disclosed as potential anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents (no data). More particularly, the invention relates to a family of compds. having both a biaryl moiety and at least one heterocyclic moiety that are useful as such agents.

ACCESSION NUMBER: 2005:182657 HCAPLUS
DOCUMENT NUMBER: 142:280195
TITLE: Preparation of biaryl heterocyclic compounds and methods of making and using the same in pharmaceutical applications
INVENTOR(S): Zhou, Jiacheng; Bhattacharjee, Ashoke; Chen, Shili; Chen, Yi; Farmer, Jay J.; Goldberg, Joel A.; Hanselmann, Roger; Lou, Rongliang; Orbin, Alia; Oyelere, Adegboyega K.; Salvino, Joseph M.; Springer, Dane M.; Tran, Jennifer; Wang, Deping; Wu, Yusheng
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019211	A2	20050303	WO 2004-US17101	20040602

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 2005203147 A1 20050915 US 2005-118808 20050429
PRIORITY APPLN. INFO.: US 2003-475430P P 20030603
US 2003-475453P P 20030603
US 2003-490855P P 20030729
US 2003-529731P P 20031215
US 2003-531584P P 20031219
US 2004-859476 A1 20040602

OTHER SOURCE(S): MARPAT 142:280195
IT 847489-40-1P 847490-40-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)
RN 847489-40-1 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-imidazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-40-8 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[[2-(1H-1,2,3-triazol-4-ylthio)ethyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 501939-95-3P 847490-64-6P 847490-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-64-6 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-65-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Jan 2005
GI



I



II

AB New oxazolidinones having a cyclopropyl moiety (I) [R1, R2 = independently H, NR5R6, CR7R8R9, C(R)2OR14, CH2NHR14, C(O)R13, C(:NOH)H, C(:NOR13)H, C(:NR13)R13, C(:NOR33)R, C(O)N(R13)2, C(O)N(R13)2, C(=NOH)N(R13)2, NHC(:X1)N(R13)2, (C:NH)R7, N(R13)C(:X1)N(R13)2, CO2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyano-C1-6 alkyl, cyano, CH:C(R)2, etc.; A = C, CH, N; --- represents an optional bond; ring A = aryl, heteroaryl, heterocyclyl; Rx = H, C1-6 alkyl; R3 = (un)substituted aromatic heterocyclic group containing at least one nitrogen in the ring which is attached through a bond on any N; R4, R4a = H, halogen, C1-6 alkoxy, C1-6 alkyl; r, s = 1-3, provided that r+s≤4; R5, R6 = H, each (un)substituted C1-6 alkyl, C1-6 acyl, or C1-6 alkylsulfonyl, etc.; R7 = H, halo, cyano, CO2R, CON(R)2, CHO, CH2NHAc, C(:NOR), OH, C1-6 alkoxy, C1-6 alkyl, alkenyl, (CH2)nNH2, etc.; R8, R9 = H, cyano, each (un)substituted C1-6 alkyl or Ph; X1 = O, S, NR13, NCN, NCO2R16, or NSO2R14; R13 = H, C1-6 alkyl, C6-10 aryl, NR5R6, SR8, S(O)R8, S(O)2R8, cyano, OH, C1-6 alkoxycarbonyl, CO2H, etc.; R14 = amino, C1-6 alkyl, C1-6 haloalkyl, (un)substituted Ph, etc.; R15 = C1-6 alkyl or (un)substituted benzyl; m, n, p, q = 0, 1], enantiomers, diastereomers, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof are prepared These compds. are effective as antibacterial agents against aerobic and anaerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides sp., Clostridia sp., as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. They are coadministered with vitamin B2, vitamin B4, vitamin B12, or folic acid to prevent or treat oxazolidinone-associated side effect such as normocytic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis,

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis. Thus, (R)-5-azidomethyl-3-[4-[(1α,5α,6α)-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]oxazolidin-2-one (370 mg) and 2,5-norbornadiene (891 mg) in dioxane (65 mL) was heated at 70° for 6 h, and then concd. in vacuo. A suspension of the residue in diethylene glycol di-Me ether (18.5 mL) was heated at 140° for 10 min to give 1-[(5R)-3-[4-[(1α,5α,6α)-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole which was treated with 12 N HCl/MeOH at room temp. for 10.5 h to give, after workup, compd. (II) (X = H). II (X = F) showed min. inhibitory concn. of 0.25, 0.25, 1, and 1 μg/mL against methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant S. pneumoniae, S. pyogenes IID692, vancomycin- and quinolone-resistant Enterococcus faecium, and Moraxella catarrhalis ATCC25238, resp.

ACCESSION NUMBER: 2005:58200 HCAPLUS
DOCUMENT NUMBER: 142:155957
TITLE: Preparation of 3-aryloxazolidin-2-one derivatives as antibiotics
INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005422	A1	20050120	WO 2004-US20738	20040629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-483901P P 20030702
US 2004-546985P P 20040224

OTHER SOURCE(S): MARPAT 142:155957

IT **828915-21-5P 828915-22-6P 828915-23-7P**
828915-24-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryloxazolidin-2-one derivs. as antibacterial agents)

RN 828915-21-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 828915-22-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-23-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(hydroxymethyl)bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-24-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxymethyl)bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **828252-93-3P 828252-94-4P 828915-25-9P**
828915-26-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazolidin-2-one derivs. as antibacterial agents)

RN 828252-93-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828252-94-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-25-9 HCAPLUS

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-26-0 HCAPLUS
CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-70-4P 501939-95-3P 828252-99-9P
828253-00-5P 828915-27-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxazolidin-2-one derivs. as antibacterial agents)
RN 501939-70-4 HCAPLUS
CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828252-99-9 HCAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 828253-00-5 HCAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-27-1 HCAPLUS
CN Bicyclo[3.1.0]hex-2-ene-6-carboxaldehyde, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Jan 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones I and II [wherein R1, R2 = independently H, NH2, CH3 and derivs., CHO and derivs., CONH2 and derivs., SO2H and derivs., (un)substituted heterocyclyl, etc.; Y, Z = (un)substituted arylene, heteroarylene; R1a = defined as R1 less H, V = O, H, OH, or halo; A = C or N with provisos; Rx = H, alkyl; R3 =NHC(:O)H and derivs., NHSO2H and derivs., (un)substituted NH-heteroaryl, etc.; B = (CH2)n; n = 0-1; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, reacting N-[[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methyl]acetamide with bis(pinacolato)diboron, and Pd-coupling with 5-bromo-2-(1-cyanocyclopropan-1-yl)pyridine gave oxazolidinone III. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium. III inhibited Staphylococcus aureus Smith in vitro with a min. inhibitory concentration of 0.06 μg/mL.

ACCESSION NUMBER: 2005:58198 HCAPLUS
DOCUMENT NUMBER: 142:155938
TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics
INVENTOR(S): Fukuda, Yasumichi
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005420	A1	20050120	WO 2004-US20737	20040629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-483904P P 20030702
US 2004-546980P P 20040224

OTHER SOURCE(S): MARPAT 142:155938
IT 827627-78-8P 827627-91-0P 827627-98-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
antibiotics)
RN 827627-75-8 HCAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-91-8 HCAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-98-5 HCAPLUS
CN Carbamic acid, [1-[5-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827627-76-9P 827627-77-0P 827627-78-1P
827627-79-2P 827627-92-9P 827627-97-4P
827627-99-6P 827628-11-5P 827628-12-6P
827628-13-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 827627-76-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-77-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-78-1 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-79-2 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-92-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-97-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6a)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827627-99-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827628-13-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-70-4P 501939-95-3P 827628-21-7P
827628-30-8P 827628-34-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 501939-70-4 HCAPLUS
CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827628-11-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-12-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-5-fluoro-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-21-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-30-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 827628-34-2 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 700370-33-8 827628-35-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827628-35-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jan 2005
GI



AB Title compds. {I; R1 = H, NR5R6, CR7R8R9, COR13, (substituted) heterocyclyl, etc.; A = NR, O, S, SO, SO2; Ar = (substituted) aryl, heteroaryl, heterocyclyl; R3 = NR13(C:X2)R12, NR13SO2R14, (substituted) heteroaryl, etc.; n = 0, 1; Rx = H, alkyl; R5, R6 = H, (substituted) alkyl, acyl, heterocyclyl, etc.; R5R6, R7R8 = atoms to form a 3-7 membered heterocyclic ring; R7 = H, halo, cyano, CHO, OH, alkyl, alkoxy, alkenyl, etc.; R8, R9 = H, cyano, (substituted) alkyl, Ph; R13 = H, alkyl, aryl, NR5R6, cyano, OH, alkylcarbonyl, CO2H, acyl, (substituted) (heterocyclic) ring, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocyclyl, Ph; X2 = O, S, NH, NSO2R14], were prepared Thus, 1-benzyloxycarbonylamino-4-[(1α,5α,6β)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]benzene in THF at -78° was treated with BuLi and then with (R)-glycidyl butyrate followed by stirring for 2 h gave 5(R)-3-[4-[(1α,5α,6β)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]-5-hydroxymethyloxazolidin-2-one. The latter was stirred 15 min. with Et3N and MeSO2Cl in CH2Cl2 at 0° to give a residue which was stirred at 70° with NaN3 in DMF to give 5(R)-azidomethyl-3-[4-[(1α,5α,6β)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-2-one. The latter was hydrogenated in THF/MeOH over Lindlar catalyst to give 5(R)-aminomethyl-3-[4-[(1α,5α,6β)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-2-one. This was stirred with Et3N and Ac2O in THF at 0°-room temperature to give N-[5(S)-3-[4-[(1α,5α,6β)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-5-ylmethyl]acetamide. The latter showed a min. inhibitory concentration of 0.25 μg/mL against Staphylococcus Aureus Smith.

ACCESSION NUMBER: 2005:55213 HCAPLUS
DOCUMENT NUMBER: 142:134582
TITLE: Preparation of oxazolidinone antibacterials
INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005399	A1	20050120	WO 2004-US20736	20040629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-483905P	P	20030702
US 2004-546947P	P	20040224
US 2004-553963P	P	20040318

OTHER SOURCE(S): MARPAT 142:134582
IT 827014-72-2P 827014-75-5P 827014-76-6P
827015-45-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of oxazolidinone antibacterials)
RN 827014-72-2 HCAPLUS
CN Bicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl]-3-oxazolidinyl]phenyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-75-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-76-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1α,5α,6β)-

L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827015-45-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jan 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones I and II [wherein R1 = H, CH3 and derivs., CHO and derivs., CN, (un)substituted heterocyclyl; Y = NH and derivs., O, CH, S, SO, SO2; A, B = (un)substituted arylene, heteroarylene, heterocyclylene, etc.; D = (CH2)n; n = 0-1; R3 = NH2 and derivs., aryl, NRC(:X2)H and derivs.; R = H, alkyl; X2 = O, S, NH, etc.; Z = substituted aromatic heterocyclic group containing 1 to 4 nitrogens and at least one double bond;; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, II•HCl was prepared by reacting N-[5(S)-3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (preparation given) with bis(pinacolato)diboron, Pd-coupling with 5-bromo-2-[(1α,5α,6β)-3-tert-butoxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridine (preparation given), and BOC-deprotection. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium. II inhibited Staphylococcus aureus Smith in vitro with a min. inhibitory concentration of 0.125 μg/mL.

ACCESSION NUMBER: 2005:55212 HCAPLUS
DOCUMENT NUMBER: 142:155937
TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics
INVENTOR(S): Fukuda, Yasumichi
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005398	A2	20050120	WO 2004-US20734	20040629
WO 2005005398	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038092	A1	20050217	US 2004-878637	20040629

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PRIORITY APPLN. INFO.: US 2003-483904P P 20030702
US 2004-546984P P 20040224

OTHER SOURCE(S): MARPAT 142:155937
IT 831201-06-0P 831201-08-2P 831201-09-3P
831201-14-0P 831201-16-2P 831201-28-6P
831201-34-4P 831201-40-2P 831201-52-6P
831201-54-8P 831201-56-0P 831201-64-0P
831201-86-6P 831201-88-8P 831201-92-4P
831201-96-8P 831201-98-0P 831202-08-5P
831202-10-9P 831202-12-1P 831202-28-9P
831202-30-3P 831202-46-1P 831202-54-1P
831202-55-2P 831202-56-3P 831202-58-5P
831202-61-0P 831202-65-4P 831202-67-6P
831202-69-8P 831202-71-2P 831202-73-4P
831202-74-5P 831202-75-6P 831202-78-9P
831222-08-3P 831222-09-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 831201-06-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[3-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-08-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-09-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-14-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-16-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-28-6 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-52-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-54-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-34-4 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-40-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-56-0 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-64-0 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-86-6 HCAPLUS
CN Carbamic acid, [1-[[(1α,5α,6β)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 831201-88-8 HCAPLUS

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(2-aminoethyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-92-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[2-hydroxy-1-(hydroxymethyl)ethyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-96-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-98-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(acetyloxy)acetyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-08-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-10-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-12-1 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[(1α,5α,6β)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 831202-28-9 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-30-3 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-46-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-54-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 831202-55-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(bromoacetyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-56-3 HCAPLUS
CN Carbamic acid, [(1α,3β,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 831202-58-5 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 831202-61-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—OBu-t

RN 831202-65-4 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

—OBu-t

RN 831202-67-6 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 831202-69-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—OBu-t

RN 831202-71-2 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-73-4 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-74-5 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-75-6 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-78-9 HCAPLUS
CN Carbamic acid, [(1α,3β,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-08-3 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

831202-17-6P 831202-18-7P 831202-19-8P
831202-20-1P 831202-21-2P 831202-22-3P
831202-23-4P 831202-24-5P 831202-27-8P
831202-29-0P 831202-31-4P 831202-32-5P
831202-33-6P 831202-34-7P 831202-37-0P
831202-42-7P 831202-45-0P 831202-53-0P
831202-57-4P 831202-59-6P 831202-63-2P
831202-64-3P 831202-66-5P 831202-81-4P
831203-07-7P 831221-99-9P 831222-02-7P
831222-03-8P 831222-06-1P 831222-07-2P
831222-10-7P 831222-11-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; prepn. of cyclopropyl-oxazolidinones as antibiotics)

RN 831201-07-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[3-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-13-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-09-4 HCAPLUS
CN Carbamic acid, [(1α,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831201-07-1P 831201-13-9P 831201-15-1P
831201-17-3P 831201-29-7P 831201-31-1P
831201-35-5P 831201-37-7P 831201-38-8P
831201-39-9P 831201-41-3P 831201-50-4P
831201-51-5P 831201-53-7P 831201-55-9P
831201-57-1P 831201-61-7P 831201-65-1P
831201-84-4P 831201-85-5P 831201-87-7P
831201-89-9P 831201-90-2P 831201-91-3P
831201-93-5P 831201-94-6P 831201-95-7P
831201-97-9P 831201-99-1P 831202-04-1P
831202-05-2P 831202-06-3P 831202-07-4P
831202-09-6P 831202-11-0P 831202-13-2P
831202-14-3P 831202-15-4P 831202-16-5P

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-15-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-17-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-29-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-31-1 HCAPLUS
CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-35-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-37-7 HCAPLUS
CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-38-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-39-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-41-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-50-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,6'-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-51-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,6'-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-53-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-55-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-57-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-61-7 HCAPLUS
CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-65-1 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 831201-84-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-methyl-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-85-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-87-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-89-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[2-(4H-1,2,4-triazol-4-yl)ethyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-90-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-morpholinylacetyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-94-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831201-95-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-fluoro-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831201-91-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(5-cyano-2-pyridinyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-93-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(2-pyrrolidinylcarbonyl)-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831201-97-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, dihydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 831201-99-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(hydroxyacetyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-04-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-05-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-methyl-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-06-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1α,5α,6β)-6-(hydroxymethyl)-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-07-4 HCAPLUS
CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-09-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831202-11-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831202-13-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-piperazinylacetyl)-, dihydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 831202-14-3 HCAPLUS
CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-thienyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-15-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-piperidinylacetyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-16-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-pyrrolidinylacetyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831202-19-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 831202-20-1 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-fluoro-2-pyrrolidinyl)carbonyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-17-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[[4-(dimethylamino)-1-piperidinyl]acetyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NMe2

RN 831202-18-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(2-pyrrolidinylcarbonyl)-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-21-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-22-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 831202-23-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-24-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-27-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-methyl-1-piperazinyl)acetyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

Me

RN 831202-29-0 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-31-4 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-32-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-(acetyloxy)-1-[(acetyloxy)methyl]ethyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-33-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1S,3R,4S)-1-azabicyclo[2.2.1]hept-3-ylcarbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-34-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(2-pyridinyl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-37-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1,2,3,4-thiatriazol-5-yl)-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-42-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-45-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-59-6 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-63-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-53-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-57-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-64-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-66-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-81-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-07-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[[(2S,4S)-4-fluoro-2-pyrrolidinyl]carbonyl]-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 831221-99-9 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-02-7 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-03-8 HCAPLUS
CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3-oxide, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-06-1 HCAPLUS
CN Carbamic acid, [(1α,3α,5α,6β)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831222-07-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-10-7 HCAPLUS
CN Carbamic acid, [(1α,3α,5α,6β)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-11-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(1α,5α,6β)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831202-60-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 831202-60-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(1α,5α,6β)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t

IT 501939-70-4P 501939-95-3P 700370-33-8P
827628-21-7P 827628-35-3P 831203-03-3P
831203-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 501939-70-4 HCAPLUS
CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-21-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-35-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-03-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-04-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831202-93-8 831203-02-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclopropyl-oxazolidinones as antibiotics)

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 831202-93-8 HCAPLUS
CN Methanesulfonic acid, trifluoro-, 2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-02-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831203-05-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 831203-05-5 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827628-34-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 827628-34-2 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Jan 2005
AB Oxazolidinones represent a new and promising class of antibacterial agents. Current research in this area is mainly concentrated on improving the safety profile and the antibacterial spectrum. Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect. Recently, it was found that the 1,2,3-triazole is a good replacement for the conventional acetamide functionality found in oxazolidinones. The authors now disclose the finding that 1,2,3-triazoles bearing a substituent like Me, small substituted Me, bromo, or a linear (sp-hybridized) group at the 4 position are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A. The results are especially promising for the development of oxazolidinones with an improved safety profile. The MAO-A SAR can be rationalized on the basis of docking studies to a MAO-A/MAO-B homol. model.
ACCESSION NUMBER: 2005:3760 HCAPLUS
DOCUMENT NUMBER: 142:211423
TITLE: Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A
AUTHOR(S): Reck, Folkert; Zhou, Fei; Girardot, Marc; Kern, Gunther; Eyermann, Charles J.; Hales, Neil J.; Ramsay, Rona R.; Gravestock, Michael B.
CORPORATE SOURCE: AstraZeneca Discovery, AstraZeneca R&D Boston, Waltham, MA, 02451, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(2), 499-506
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:211423
IT 371195-02-7
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)
RN 371195-02-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 591253-34-8P 591253-50-8P 591253-54-2P
591253-95-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)
RN 591253-34-8 HCAPLUS
CN Phosphoric acid, [1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-50-8 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 591253-54-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-95-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(trimethylsilyl)ethynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **591231-84-4P 591231-97-9P 591232-00-7P**
591253-26-8P 591253-36-0P 591253-60-0P
591253-77-9P 591253-78-0P 591253-81-5P
591253-82-6P 591253-94-0P 844493-91-0P

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
844493-92-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)
RN 591231-84-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(1-methylethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591231-97-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-00-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-26-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-36-0 HCAPLUS
CN 1H-1,2,3-Triazole-4-acetonitrile, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-60-0 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-[(1E)-2-bromoethenyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-77-9 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-bromo-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-78-0 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-94-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 844493-91-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-81-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-82-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 844493-92-1 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Oct 2004
GI



I



II

AB Title compds. I [A = oxazolyl, isoxazolyl, etc.; n = 0-1; Y = SO0-2, O, amino; Z = formyl, thioformyl, acyl, etc.; W = CH2, CO, oximino, etc.; R1 = H, OH, amino, etc.; R2-3 = H, F; R4-5 = H, Cl, F, Me, NH2, OH; R6-7 = H, alkyl] are prepared For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4 μg/mL for S. aureus (UC9213). I are antibacterial agents.

ACCESSION NUMBER: 2004:872795 HCAPLUS
DOCUMENT NUMBER: 141:366217
TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials
INVENTOR(S): Renslo, Adam Robert; Gordeev, Mikhail Fedor; Patel, Dinesh Vinoobhai; Gao, Hongwu; Josyula, Vara Prasad Venkata Nagendra
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, LLC, USA
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089943	A1	20041021	WO 2004-IB1135	20040330
WO 2004089943	C1	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005192325 A1 20050901 US 2004-815589 20040401
PRIORITY APPLN. INFO.: US 2003-461134P P 20030409
OTHER SOURCE(S): MARPAT 141:366217
IT 777088-83-2P 777089-13-1P 777089-14-2P 777089-15-3P 777089-16-4P 777089-17-5P 777089-18-6P 777089-23-3P 777089-24-4P 780766-88-3P 780766-89-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777088-83-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-13-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(1α,5α,6α)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-14-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(1α,5α,6α)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-15-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-16-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-17-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1α,5α,6α)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-18-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1α,5α,6α)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-23-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-24-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 780766-88-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1α,5α,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-89-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1α,5α,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 777090-03-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
antimicrobials)
RN 777090-03-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1α,5α,6α)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Sep 2004
GI



AB Title compds. [I; HET = pyrazolyl, imidazolyl, triazolyl, tetrazolyl; Q = (substituted) azolylphenyl, azolylpyridinyl, azolyloxazolyl, azolylthiazolyl, etc.], were prepared Thus, (R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given), (PPh3)2PdCl2, and 5-tributylstannyl-3-methylisoxazole were heated together at 100° in dioxane for 16 h to give title compound (II). II showed a min. inhibitory concentration of 1 μg/mL against Staphylococcus aureus MSQS (methicillin resistant and quinolone resistant).

ACCESSION NUMBER: 2004:799584 HCAPLUS
DOCUMENT NUMBER: 141:296028
TITLE: Preparation of azolylmethyloxazolidinones as antibacterials.
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083206	A1	20040930	WO 2004-GB1132	20040316

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-6357 A 20030320
OTHER SOURCE(S): MARPAT 141:296028
IT 765286-96-2P 765286-97-3P 765286-98-4P
765286-99-5P 765287-00-1P 765287-01-2P
765287-02-3P 765287-03-4P 765287-04-5P
765287-05-6P 765287-06-7P 765287-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of azolylmethyloxazolidinones as antibacterials)
RN 765286-96-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-97-3 HCAPLUS
CN 3-Isoxazolecarboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-98-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-(hydroxymethyl)-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-99-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonooxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 765287-00-1 HCAPLUS
CN 1H-Pyrazole-5-carbonitrile, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-01-2 HCAPLUS
CN 1H-Pyrazole-5-carboxaldehyde, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-02-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 765287-03-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-methyl-1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-04-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-05-6 HCAPLUS
CN 1H-1,2,3-Triazole-1-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 765287-06-7 HCAPLUS
CN 2H-1,2,3-Triazole-2-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-18-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonooxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, disodium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

IT 501939-95-3P 765287-07-8P 765287-15-8P
765287-16-9P 765287-17-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolylmethyloxazolidinones as antibacterials)

RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-07-8 HCAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-15-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-[(4-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-16-9 HCAPLUS
CN 2-Oxazolidinone, 3-(4-ethynyl-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 765287-17-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(trimethylsilyl)ethynyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 2003-6358 A 20030320
OTHER SOURCE(S): MARPAT 141:314336
IT **765912-32-1P 765912-34-3P 765912-36-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)
RN 765912-32-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-34-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-36-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-(phenylmethyl)-1H-1,2,3-triazol-4-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Sep 2004
GI



I



II

AB Title compds. represented by the formula I [wherein N-HET = (un)substituted 1-pyrazolyl, 1-imidazolyl, 1,2,3-triazol-1-yl, etc.; Q = (un)substituted heteroaryl Ph, pyridinyl, thienyl, etc.; and pharmaceutically acceptable salts or an in-vivo hydrolyzable ester thereof] were prepared as MAO-A (mono-amine oxidase) inhibitors. For example, coupling reaction of (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one with 5-(tributylstannyl)-3-methylisoxazole gave II. II showed decreased MAO-A potency with Ki value of 21 μg/mL. Thus, I and their pharmaceutical compns. are useful as antibacterial agents.
ACCESSION NUMBER: 2004:799583 HCAPLUS
DOCUMENT NUMBER: 141:314336
TITLE: Preparation of 1,3-oxazolidin-2-one derivatives as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083205	A1	20040930	WO 2004-GB1119	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **501939-98-6P 501940-28-9P 765912-54-7P**
765912-55-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)
RN 501939-98-6 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-28-9 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-54-7 HCAPLUS
CN 2-Oxazolidinone, 3-(4-ethynyl-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 765912-55-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(trimethylsilyl)ethynyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
triazol-4-yl]methyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 756825-24-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-oxopropyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Bifunctional heterocyclic glycosides I were prepared, wherein X is a linear linker; Y is heterocycle; J is H, macrocycle, acyl, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic carbocycle, L is CO, CO2, amide; n is 0-1; R1-R3 are independently H, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic; R2R3 together with the N atom to which they are bonded, form 5-7 membered saturated, unsatd., or aromatic heterocycle; useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. Thus, macrolide glycoside II was prepared as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agent (no biol. data).

ACCESSION NUMBER: 2004:756728 HCAPLUS
DOCUMENT NUMBER: 141:260999
TITLE: Preparation of bifunctional heterocyclic azithromycin compounds useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents
INVENTOR(S): Farmer, Jay J.; Sutcliffe, Joyce A.; Bhattacharjee, Ashoke
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078770	A1	20040916	WO 2004-US6892	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517970	AA	20040916	CA 2004-2517970	20040305
PRIORITY APPLN. INFO.:			US 2003-451951P	P 20030305
			WO 2004-US6892	W 20040305

OTHER SOURCE(S): MARPAT 141:260999
IT 756825-22-6P 756825-24-8P 756825-25-9P 756825-26-0P
RL: BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bifunctional heterocyclic azithromycin compds. useful as antiinfective antiproliferative antiinflammatory and prokinetic agents)
RN 756825-22-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 756825-25-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-β-D-glucopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 756825-26-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]carbonyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Sep 2004
GI



I



II

AB The title compds. I [R1 = -NH(C=W)R5 or (substituted)1,2,3-Triazolyl; W = O or S; R2, R3 = H, F, Cl, CF3, OMe, SMe, and Et; R5 = H, alkyl, Me, 5-halo-2-thienyl, etc.; R4 = hydroxymethyl] were prepared as antibacterial agents. For example, compound II was prepared from (5R)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one in a multi-step synthesis. Antibacterial properties of II against several types of bacteria were determined [MIC(μg/mL): methicillin sensitive and quinolone sensitive staphylococcus aureus (0.25), methicillin resistant and quinolone resistant staphylococcus aureus (0.5), streptococcus pneumoniae (0.02), haemophilus influenza (4), and Moraxella catarrhalis (0.5)].

ACCESSION NUMBER: 2004:756715 HCAPLUS
DOCUMENT NUMBER: 141:260739
TITLE: Preparation of hydroxymethyl dihydroisoxazole derivatives useful as antibiotic agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Carcanague, Daniel Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078753	A1	20040916	WO 2004-GB730	20040224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CA 2517706	AA	20040916	CA 2004-2517706	20040224
PRIORITY APPLN. INFO.:			GB 2003-4723	A 20030301
			GB 2003-18607	A 20030808
			WO 2004-GB730	W 20040224

OTHER SOURCE(S): MARPAT 141:260739
IT 702681-58-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)
RN 702681-58-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 756873-54-8P 756873-57-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)
RN 756873-54-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5R)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 756873-57-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501939-95-3P 700370-33-8P 700370-36-1P**
700370-37-2P 700370-39-4P 700370-40-7P
756874-06-3P 756874-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)

RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756874-06-3 HCAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-36-1 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-39-4 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(hydroxymethyl)-1H-1,2,3-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756874-09-6 HCAPLUS
CN β-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

IT **756873-76-4P 756873-84-4P 756873-87-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(pro-drug; preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)

RN 756873-76-4 HCAPLUS
CN Glycine, N,N-dimethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 756873-84-4 HCAPLUS
CN Pentanoic acid, 5-[[(1,1-dimethylethoxy)carbonyl]methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
756874-04-1P 756874-05-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pro-drug; prepn. of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)
RN 702681-56-9 HCAPLUS
CN β-Alanine, N,N-diethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 702681-66-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 756873-87-7 HCAPLUS
CN Pentanoic acid, 5-(methylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

IT 702681-56-9P 702681-66-1P 702682-78-8P
756873-58-2P 756873-59-3P 756873-60-6P
756873-61-7P 756873-62-8P 756873-63-9P
756873-64-0P 756873-65-1P 756873-66-2P
756873-67-3P 756873-68-4P 756873-69-5P
756873-70-8P 756873-71-9P 756873-72-0P
756873-73-1P 756873-74-2P 756873-75-3P
756873-77-5P 756873-78-6P 756873-79-7P
756873-80-0P 756873-81-1P 756873-82-2P
756873-83-3P 756873-85-5P 756873-86-6P
756873-88-8P 756873-89-9P 756873-91-3P
756873-92-4P 756873-93-5P 756873-94-6P
756873-95-7P 756873-96-8P 756873-97-9P
756873-98-0P 756873-99-1P 756874-00-7P
756874-01-8P 756874-02-9P 756874-03-0P

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-78-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[[(2-methoxyethoxy)methoxy]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-58-2 HCAPLUS
CN Hexanedioic acid, ethyl [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 756873-59-3 HCAPLUS
CN β-Alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-60-6 HCAPLUS
CN Butanoic acid, 4-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 756873-62-8 HCAPLUS
CN Acetic acid, methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-63-9 HCAPLUS
CN Propanoic acid, 3-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-64-0 HCAPLUS
CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-61-7 HCAPLUS
CN Pentanoic acid, 5-[(methoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-65-1 HCAPLUS
CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-66-2 HCAPLUS
CN Pentanedioic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 756873-67-3 HCAPLUS
CN Butanoic acid, 4-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, diammonium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-71-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(sulfooxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-72-0 HCAPLUS
CN 4-Piperidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 756873-68-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(acetyloxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-69-5 HCAPLUS
CN 1,2-Cyclohexanedicarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-70-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(phosphonooxy)methyl]-3-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756873-73-1 HCAPLUS
CN Pentanoic acid, 5-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-74-2 HCAPLUS
CN Butanedioic acid, mono[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 756873-75-3 HCAPLUS
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 756873-79-7 HCAPLUS
CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 3-methoxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-80-0 HCAPLUS
CN Pyrazinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 756873-77-5 HCAPLUS
CN Pentanoic acid, 5-[(ethoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-78-6 HCAPLUS
CN Ethanaminium, 2-[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy]-N,N,N-trimethyl-2-oxo-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 756873-81-1 HCAPLUS
CN 5-Pyrimidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-82-2 HCAPLUS
CN Ethanaminium, 2-[[[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy]carbonyl]oxy]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



● Cl-

PAGE 1-B

RN 756873-83-3 HCAPLUS
CN Pentanoic acid, 5-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 756873-88-8 HCAPLUS
CN Pentanoic acid, 5-[[(dimethylamino)acetyl]methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 756873-85-5 HCAPLUS
CN Butanoic acid, 4-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 756873-86-6 HCAPLUS
CN Hexanoic acid, 6-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 756873-89-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(5S)-5-[(β-D-glucopyranosyloxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-91-3 HCAPLUS
CN Glycine, N-methyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-92-4 HCAPLUS
CN L-Alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-93-5 HCAPLUS
CN L-Valine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-96-8 HCAPLUS
CN L-Isoleucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-97-9 HCAPLUS
CN L-Glutamine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 756873-94-6 HCAPLUS
CN L-Leucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 756873-95-7 HCAPLUS
CN Glycine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756873-98-0 HCAPLUS
CN L-Aspartic acid, 1-[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 756873-99-1 HCAPLUS
CN L-Aspartic acid, 4-[[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 756874-00-7 HCAPLUS
CN L-Lysine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 756874-03-0 HCAPLUS
CN Acetic acid, [2-[(methoxycarbonyl)methylamino]ethoxy]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 756874-04-1 HCAPLUS
CN Acetic acid, [2-(methylamino)ethoxy]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 756874-01-8 HCAPLUS
CN L-Phenylalanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756874-02-9 HCAPLUS
CN L-Proline, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B

RN 756874-05-2 HCAPLUS
CN L-Isoleucine, N-methyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Jul 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-R8 = H, halo, NH2, glycylamino, (un)substituted alkoxy; T, Q = halo, OH, (un)substituted C1-8 alkoxy, (un)substituted C1-8 alkanoyloxy, NH2, N3, (un)substituted unsatd. heterocyclyl, etc.], useful for controlling (drug-resistant) bacteria, are prepared by conversion of 3-(substituted phenyl)-2-oxooxazolidines II (R1-R4, Q = same as above; X = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue) into 3-(boron-substituted phenyl)-2-oxooxazolidines II [R1-R4, Q = same as above; X = BR9R10; R9, R10 = OH, C1-8 linear alkyl(oxy), C3-8 branched alkyl(oxy); R9R10 may be linked], then coupling with oxazolidinylbenzenes III (R5-R8, T = same as above; Y = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue). Thus, coupling of 3-(3-fluoro-4-iodophenyl)-2-oxo-5(R)-phthalimidomethyloxazolidine with 5(S)-acetamidomethyl-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxooxazolidine in the presence of K phosphate and tetrakis(triphenylphosphine)palladium in DMF gave the corresponding biphenyl compound with 66% yield, which showed MIC of 2 μg/mL against methicillin-resistant Staphylococcus aureus.

ACCESSION NUMBER: 2004:588234 HCAPLUS
DOCUMENT NUMBER: 141:140417
TITLE: Preparation of novel biphenyls, their intermediates, and their use as bactericides
INVENTOR(S): Shiokawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Fujita, Toshiki; Maehashi, Kazunori; Yoshida, Satoshi
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 185 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004203809	A2	20040722	JP 2002-376218	20021226
PRIORITY APPLN. INFO.:			JP 2002-376218	20021226
OTHER SOURCE(S):	MARPAT 141:140417			

IT **724793-19-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (oxooxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)
RN 724793-19-5 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

NHAc

IT **724792-94-3P 724793-13-9P 724793-15-1P**
724793-20-8P 724793-78-6P 724793-79-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (oxooxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)
RN 724792-94-3 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-13-9 HCAPLUS
CN Carbamic acid, [2-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OBu-t

RN 724793-15-1 HCAPLUS
CN Acetamide, 2-amino-N-[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-14-0
CMF C24 H23 F2 N7 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

MF C2 H F3 O2

RN 724793-20-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-[4'-[(5R)-5-[[5-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-78-6 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 724793-79-7 HCAPLUS
CN Acetamide, N-[[(5S)-3-[4'-[(5R)-5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-95-3P 724793-90-2P 724793-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (oxooxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 724793-90-2 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-91-3 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Jul 2004
GI



I



II



III

AB The invention relates to a preparation of oxazolidinone derivs. of formula R1-A-C-B-CH2-R2 [wherein: A and B are independently selected from oxazolidinone or isoxazole derivs.; C is a biaryl group C1-C2 where C1 is benzene-1,4-diyl, thiene-2,5-diyl, or pyridine-2,5-diyl, etc., and C2 is pyridazine-3,6-diyl, pyrazine-2,5-diyl, pyrimidine-2,5-diyl, or 1,3,4-thiadiazole-2,5-diyl, etc.; R1 is CN, C(O), (un)substituted Ph or naphthyl, cycloalkyl, or heteroaryl, etc.; R2 is OH, OSi(trialkyl), or NHC(O)Me, etc.], useful as antibacterial agents. For instance, oxazolidinone derivative I was prepared from the obtained bromopyrimidine derivative
II and obtained trimethylstannylphenyloxazole derivative III in the presence of palladium catalyst. For instance, antibacterial properties of I against several types of bacteria were determined [MIC(μg/mL): staphylococcus aureus (2), streptococcus pneumoniae (0.25), haemophilus influenza (8)].

ACCESSION NUMBER: 2004:550955 HCAPLUS
DOCUMENT NUMBER: 141:89124
TITLE: A preparation of oxazolidinone derivatives, useful as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Huynh, Hoan Khai
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056817	A1	20040708	WO 2003-GB5448	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1572688	A1	20050914	EP 2003-768000	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-29526	A 20021219
			WO 2003-GB5448	W 20031215

OTHER SOURCE(S): MARPAT 141:89124
IT 501939-94-2P 501939-95-3P 700370-36-1P
700370-37-2P 700370-39-4P 700370-40-7P
716379-10-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolidinone derivs., useful as antibacterial agents)
RN 501939-94-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-36-1 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-39-4 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 700370-40-7 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-10-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



IT 716379-02-1P 716379-05-4P 716379-09-8P
716379-12-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinone derivs., useful as antibacterial agents)
RN 716379-02-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[2-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-5-

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyrimidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-05-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-5-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-09-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 716379-12-3 HCAPLUS

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[4-[2-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-5-pyrimidinyl]-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Jun 2004
GI



II

AB Title compds. (R1a)m-A-C-B-CH2-R1b [C = biaryl group; A, B = dihydroisoxazole, oxazolidinone; R1a = CN, carboxy, alkoxycarbonyl, aryl, etc.; m = 0-2; R1b = OH, silyloxy, etc.; I] are prepared For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to 5,5-bis[[(tert-butyldimethylsilyl)oxy]methyl]-3-[4-(trimethylstannyl)phenyl]-4,5-dihydroisoxazole (preparation given) (NMP, (furan-2-yl)3P, dba3Pd2) and the resulting adduct desilylated (THF, TBAF) to give II. II exhibits MIC = 0.5 μg/mL against Staphylococcus aureus; compds. of the invention are antibacterial agents.

ACCESSION NUMBER: 2004:467903 HCAPLUS
DOCUMENT NUMBER: 141:38599
TITLE: Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents
INVENTOR(S): Carcanague, Daniel Robert; Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048392	A1	20040610	WO 2003-GB5087	20031124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CA 2507468	AA	20040610	CA 2003-2507468	20031124
EP 1567532	A1	20050831	EP 2003-811807	20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016688	A	20051018	BR 2003-16688	20031124
PRIORITY APPLN. INFO.:			GB 2002-27702	A 20021128
			GB 2003-4725	A 20030301
			GB 2003-18608	A 20030808
			WO 2003-GB5087	W 20031124

OTHER SOURCE(S): MARPAT 141:38599
IT **501940-91-6P 702679-77-4P**, (5R)-3-[4'-[5,5-Bis[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **702679-98-9P**, (5R)-3-[4'-[5,5-Bis[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **702680-89-5P 702680-93-1P 702681-83-2P**, (5R)-3-[4-[6-[(5S)-5-((1R)-1,2-Dihydroxyethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)
RN 501940-91-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702679-77-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702679-98-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-89-5 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 702679-95-6P, (5R)-3-[4'-[5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-03-3P, (5R)-3-[4'-[5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-11-3P 702680-16-8P, (5R)-3-[4'-(4,5-Dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-21-5P, (5R)-3-[4'-(4,5-Dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-23-7P, (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-35-1P, (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 702680-46-4P 702680-51-1P 702680-61-3P 702680-65-7P 702680-69-1P 702680-73-7P, (5R)-3-[3-Fluoro-4-[6-(5,5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-85-1P 702680-95-3P 702680-99-7P 702681-01-4P 702681-07-0P 702681-11-6P 702681-15-0P 702681-20-7P 702681-22-9P 702681-26-3P 702681-31-0P 702681-39-8P 702681-40-1P 702681-42-3P 702681-44-5P 702681-47-8P 702681-54-7P 702681-56-9P 702681-61-6P 702681-64-9P 702681-66-1P 702681-69-4P 702681-71-8P 702681-73-0P 702681-87-6P, (5R)-3-[4-[6-[(5R)-5-((1R)-1,2-Dihydroxyethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702681-97-8P, (5R)-3-[4-[6-[(5S)-5-((1S)-1,2-Dihydroxyethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-01-7P, (5R)-3-[4-[6-[(5R)-5-((1S)-1,2-Dihydroxyethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-13-1P, (5R)-3-[4-[6-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-21-1P 702682-26-6P 702682-29-9P 702682-32-4P 702682-43-7P, (5R)-3-[3-Fluoro-4-[6-[(5S)-5-[[(2-hydroxyethyl)thio]methyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-56-2P 702682-72-2P 702682-78-8P 702682-88-0P

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-93-1 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-83-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702679-95-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-03-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-11-3 HCAPLUS
CN 5-Isoxazoleacetonitrile, 3-[2'-fluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-16-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-21-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-23-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-35-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-46-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-1-oxido-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-51-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(tetrahydro-3-hydroxy-1,1-dioxido-3-thienyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-61-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxy-1-methylethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-65-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-4,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-69-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[5-(2,2-diethoxyethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-73-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-99-7 HCAPLUS
CN 5-Isoxazolecarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-01-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[(2-hydroxyethyl)sulfonyl]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-85-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(2-hydroxyethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-95-3 HCAPLUS
CN 5-Isoxazolecarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-07-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxyphenylmethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-11-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxycyclopentyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-15-0 HCAPLUS
CN 1-Naphthaleneacetic acid, 1-[3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 702681-20-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxy-2-methylpropyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-22-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[[2-(4-pyridinyl)ethyl]amino]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 702681-26-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(4-hydroxy-1-methyl-4-piperidinyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-31-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[[2-(4-pyridinyl)ethyl]sulfonyl]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 702681-39-8 HCAPLUS
CN Glycine, N,N-dimethyl-, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 702681-40-1 HCAPLUS
CN Pentadecanoic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-42-3 HCAPLUS
CN 2,5,8,11,14-Pentaoxapentadecanoic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 702681-44-5 HCAPLUS

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-56-9 HCAPLUS
CN β-Alanine, N,N-diethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 702681-61-6 HCAPLUS
CN Butanedioic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 702681-60-5
CMF C26 H25 F N6 O7

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Piperidinecarboxylic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-47-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(phosphonooxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, diammonium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 NH_3

RN 702681-54-7 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 702681-64-9 HCAPLUS
CN Butanedioic acid, ethyl [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 702681-63-8
CMF C27 H27 F N6 O7

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—OEt

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 702681-66-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 702681-71-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[[(4-nitrobenzoyl)oxy]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO2

RN 702681-73-0 HCAPLUS
CN Butanedioic acid, mono[[3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-69-4 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 702681-68-3
CMF C27 H29 F N6 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-t

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—CO2H

RN 702681-87-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-97-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-01-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-13-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-21-1 HCAPLUS
CN Propanoic acid, 3-methoxy-, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 702682-26-6 HCAPLUS
CN 3-Pyridinecarboxylic acid, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 702682-29-9 HCAPLUS
CN Carbonic acid, (2R)-2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxyethyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 702682-32-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[5-[(1R)-1,2-bis(phosphonooxy)ethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, tetraammonium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 4 NH_3

RN 702682-43-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[[(2-hydroxyethyl)thio]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-56-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(trifluoromethoxy)methyl]-3-

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-72-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2,2,2-trifluoroethoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-78-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[[(2-methoxyethoxy)methoxy]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-27-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-36-1 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501939-95-3P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-28-9P**, (5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-33-8P** **700370-37-2P**

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—OMe

RN 702682-88-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(methoxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501939-98-6**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-27-8**, (5R)-3-[3-Fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-36-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)
RN 501939-98-6 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
702680-25-9P, (5R)-3-[4'-[5,5-Bis[[(tert-butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **702680-37-3P**, (5R)-3-[4'-[5,5-Bis[[(tert-butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one **702680-97-5P** **702681-49-0P** **702681-58-1P** **702681-85-4P** **702681-99-0P** **702682-16-4P**, (5R)-3-[4-[6-[5,5-Bis[[(tert-butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **702682-35-7P** **702682-37-9P** **702682-47-1P**, (5R)-3-[4-[6-[(5S)-5-(Chloromethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-28-9 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-37-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-25-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702680-37-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-97-5 HCAPLUS
CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-, pentafluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-49-0 HCAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-58-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702681-85-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-99-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-16-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-35-7 HCAPLUS
CN Phosphoric acid, (1R)-1-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-1,2-ethanediyl tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 702682-37-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1R)-1,2-bis(phosphonooxy)ethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-47-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-(chloromethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Jun 2004
GI



II

AB Isoxazolinyl oxazolidinone compds. of formula I (R1CH2-A-C-B-CH2R2 [A, B = oxazolidinone, isoxazoline; C = (substituted) bisaryl group; R1, R2 = OH, trialkylsilyloxy, acyloxy, heteroaryl, etc.]) are prepared as antibacterial agents. Methods for making compds. of formula I, compns. containing them and their use as antibacterial agents are also described. Thus, II was prepared, and had MIC of 0.5 μg/mL against Staphylococcus aureus.

ACCESSION NUMBER: 2004:467887 HCAPLUS
DOCUMENT NUMBER: 141:23522
TITLE: Preparation of isoxazolinyl oxazolidinone antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048370	A1	20040610	WO 2003-GB5082	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1567521	A1	20050831	EP 2003-811806	20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: GB 2002-27701 A 20021128
WO 2003-GB5082 W 20031124

OTHER SOURCE(S): MARPAT 141:23522
IT 698981-84-9P 698981-94-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoxazolinyl oxazolidinone antibacterial agents)
RN 698981-84-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 698981-94-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 698981-89-4P 698981-99-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazolinyl oxazolidinone antibacterial agents)
RN 698981-89-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 698981-99-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-95-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazolinyl oxazolidinone antibacterial agents)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Jun 2004
GI



I



II

AB Title compds. I [C = substituted biaryl; R1 = HET1, HET2; HET1 = N-linked 5-membered (un)saturated heterocyclic ring, etc.; HET2 = N-linked 6-membered dihydroheteroaryl ring, etc.] are prepared For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to bis(pinacolato)diboron (DMSO, PdCl2(dppf)•CH2Cl2, KOAc) and the resulting adduct coupled to 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (DMF, H2O, K2CO3, (PPh3)4Pd) to give II. Compds. of the invention exhibit antibacterial activity with MIC = 0.01 - 256 μg/mL; II has MIC < 0.06 for Streptococcus pneumoniae.

ACCESSION NUMBER: 2004:467876 HCAPLUS
DOCUMENT NUMBER: 141:23521
TITLE: Preparation of substituted oxazolidinones as antibiotics
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048350	A2	20040610	WO 2003-GB5091	20031124
WO 2004048350	A3	20041021		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2507628	AA	20040610	CA 2003-2507628		20031124
EP 1581524	A2	20051005	EP 2003-778506		20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016690	A	20051018	BR 2003-16690		20031124
PRIORITY APPLN. INFO.:			GB 2002-27704	A	20021128
			GB 2003-10828	A	20030510
			WO 2003-GB5091	W	20031124

OTHER SOURCE(S): MARPAT 141:23521

IT **700370-32-7P**, (5R)-3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **700370-35-0P**, (5R)-3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-41-8P**, (5R)-3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-5-(4-chloro-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **700370-44-1P**, (5R)-3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-1-oxopyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **700370-46-3P**, (5R)-3-[3-Fluoro-4-[6-[2-(2-hydroxyethyl)-2H-1,2,3,4-tetrazol-5-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-one **700370-48-5P**, (5R)-3-[3-Fluoro-4-[6-[1-(propane-1,3-diol-2-yl)-1H-1,2,3,4-tetrazol-5-yl]-3-pyridinyl]phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **700370-51-0P**, (5R)-5-[[4-(Difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl]-1,3-oxazolidin-2-one **700370-55-4P**, (5R)-3-[3-Fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)pyridin-3-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: FAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazolidinones as antibiotics)

RN 700370-32-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-35-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-41-8 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-44-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-1-oxido-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-46-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(2-hydroxyethyl)-2H-tetrazol-5-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-48-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-[2-hydroxy-1-(hydroxymethyl)ethyl]-1H-

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

tetrazol-5-yl]-3-pyridinyl]phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-51-0 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-55-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **700370-42-9**, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted oxazolidinones as antibiotics)
RN 700370-42-9 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501939-95-3P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **700370-33-8P 700370-34-9P 700370-36-1P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-37-2P**, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-38-3P 700370-39-4P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-hydroxymethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-40-7P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-bromomethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-43-0P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **700370-52-1P**, (5R)-5-[[4-(Difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazolidin-2-one **700370-53-2P**, (5R)-5-[[4-(Difluoromethyl)-1H-1,2,3-triazol-1-

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

yl]methyl]-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one **700370-34-9P**, 1-[[(5R)-3-(3-Fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-1H-1,2,3-triazole-4-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted oxazolidinones as antibiotics)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-34-9 HCAPLUS
CN Boronic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-36-1 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-38-3 HCAPLUS
CN Boronic acid, [2-fluoro-4-[(5R)-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 700370-39-4 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-43-0 HCAPLUS

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 5-[[4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-52-1 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-53-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-54-3 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Apr 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazolyl, dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)n; n = 0-1; X = N, CH; Y = N, O, S; Z = NHCOR1, NHCSR1, CONHR1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylamino-1-chloromethylethyl ester afforded oxazolidinone III in 62% yield. In S. aureus Min. Inhibitory Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 μg/mL, i.e., the MIC value of oxazolidinone III was 1 μg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

ACCESSION NUMBER: 2004:333714 HCAPLUS
DOCUMENT NUMBER: 140:357327
TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents
INVENTOR(S): Gordeev, Mikhail Fedor; Renslo, Adam; Patel, Dinesh Vinoobhai
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127530	A1	20040701	US 2003-677451	20031002
US 6875784	B2	20050405		
CA 2501352	AA	20040422	CA 2003-2501352	20031003
EP 1549641	A1	20050706	EP 2003-770310	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015106	A	20050809	BR 2003-15106	20031003

PRIORITY APPLN. INFO.: US 2002-417735P P 20021009
WO 2003-US28560 W 20031003

OTHER SOURCE(S): MARPAT 140:357327
IT 681424-73-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)
RN 681424-73-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1α,5α,6α)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 681424-72-6
CMF C18 H17 F2 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 681425-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)
RN 681425-60-5 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Apr 2004
GI



I

II

AB Oxopyridinylphenyl oxazolidinones, e.g. of formula I [W = O, S; R1 = NH2, NH-alkyl, alkyl, alkoxy, etc.; R2, R3 = H, Cl, F, Me, NH2, OH; R4 = H, halo, NH2, OH, CN, alkyl, alkoxy, etc.], are prepared as antibacterial agents which have activity against both Gram-pos. and Gram-neg. bacteria. Thus, II was prepared, and had MIC of 1 μg/mL against HINF 30063.

ACCESSION NUMBER: 2004:333712 HCAPLUS
DOCUMENT NUMBER: 140:339319
TITLE: Preparation of oxopyridinylphenyl oxazolidinones as Gram-positive and Gram-negative antibacterial agents
INVENTOR(S): Gordeev, Mikhail Fedor; Singh, Upinder; Patel, Dinesh Vinoobhai; May, Paul Dennis
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033449	A1	20040422	WO 2003-IB4380	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499105	AA	20040422	CA 2003-2499105	20031003
EP 1554273	A1	20050720	EP 2003-807940	20031003

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003015206	A	20050816	BR 2003-15206		20031003
US 2005070580	A1	20050331	US 2004-497626		20040603
PRIORITY APPLN. INFO.:			US 2002-417492P	P	20021010
			WO 2003-IB4380	W	20031003

OTHER SOURCE(S): MARPAT 140:339319
IT **680614-95-3P 680614-96-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxopyridinylphenyl oxazolidinones as antibacterial agents)
RN 680614-95-3 HCAPLUS
CN 4(1H)-Pyridinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 680614-96-4 HCAPLUS
CN 4(1H)-Pyridinone, 2,3-dihydro-1-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Apr 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I [A = C, C(:O), N (with proviso, that at least one A = C); B = O, NR2, S(O)r, C(:O), C(:S), C(:NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)rR4, CHO, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(:O)NR3R3, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional hetercyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTs, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004:292029 HCAPLUS
DOCUMENT NUMBER: 140:321158
TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents
INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Mcconnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005197334 A1 20050908 US 2003-671326 20030925
CA 2500158 AA 20040408 CA 2003-2500158 20030926
EP 1543017 A2 20050622 EP 2003-770506 20030926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-414207P P 20020926
US 2003-448216P P 20030219
WO 2003-US30478 W 20030925
OTHER SOURCE(S): MARPAT 140:321158

IT 677726-23-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-alkylation by, of des(N-methyl)erythromycin; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-23-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[2-[[(4-methylphenyl)sulfonyl]oxy]ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 677726-15-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and N-dealkylation of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-15-7 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 677726-17-9P 677726-31-7P 677726-85-1P 677726-86-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and hydrolysis of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-17-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-31-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-85-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-86-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



IT 677726-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of; preparation of bifunctional heterocyclic compds.
for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-19-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-(3-hydroxypropyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 677726-37-3P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and tosylation of; preparation of bifunctional heterocyclic compds.
for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
RN 677726-37-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 677726-11-3P 677726-12-4P 677726-13-5P
677726-14-6P 677726-16-8P 677726-18-0P
677726-26-0P 677726-27-1P 677726-28-2P
677726-29-3P 677726-30-6P 677726-33-9P
677726-34-0P 677726-35-1P 677726-36-2P
677726-46-4P 677726-47-5P 677726-48-6P
677726-49-7P 677726-50-0P 677726-51-1P
677726-52-2P 677726-53-3P 677726-54-4P
677726-55-5P 677726-57-7P 677726-58-8P

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

677726-60-2P 677726-62-4P 677726-63-5P
677726-65-7P 677726-66-8P 677726-68-0P
677726-70-4P 677726-72-6P 677726-73-7P
677726-74-8P 677726-75-9P 677726-76-0P
677726-77-1P 677726-78-2P 677726-79-3P
677726-80-6P 677726-81-7P 677726-82-8P
677726-83-9P 677726-84-0P 677726-87-3P
677726-88-4P 677726-89-5P 677726-90-8P
677727-77-4P 677727-78-5P 677727-79-6P
677727-80-9P 677727-81-0P 677727-82-1P
677727-83-2P 677727-84-3P 677727-85-4P
677727-86-5P 677727-87-6P 677727-88-7P
677727-89-8P 677727-90-1P 677727-91-2P
677727-92-3P 677727-93-4P 677727-94-5P
677727-95-6P 677727-96-7P 677727-97-8P
677727-98-9P 677727-99-0P 677728-00-6P
677728-01-7P 677728-02-8P 677728-03-9P
677728-04-0P 677729-42-9P 678182-71-3DP,
trans-cyclohexanol isomers
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-11-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[[(2-hydroxyethyl)methylamino]methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-12-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[2-[(2-hydroxyethyl)methylamino]ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-16-8 HCAPLUS
CN Erythromycin, N-demethyl-N-[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-13-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[3-[(2-hydroxyethyl)methylamino]propyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-14-6 HCAPLUS
CN D-xylo-Hexose, 3,4,6-trideoxy-3-[[[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 677726-18-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-26-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 677726-27-1 HCAPLUS
CN Erythromycin, N-[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 677726-28-2 HCAPLUS
CN Erythromycin, N-[3-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

PAGE 2-A



RN 677726-29-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-30-6 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 677726-33-9 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-35-1 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-34-0 HCAPLUS
CN Erythromycin, N-[2-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-36-2 HCAPLUS
CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 677726-46-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-47-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-48-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-49-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[4-[[2-(acetyloxy)ethyl]methylamino]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-50-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-51-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-(3-pyridinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-52-2 HCAPLUS
CN Erythromycin, N,N-didemethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 677726-53-3 HCAPLUS
CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-N-demethyl-N-[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-54-4 HCAPLUS
CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 677726-55-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-57-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-58-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4'-cyano-2-fluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-60-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-62-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-63-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(4-cyano-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-,

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-65-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-66-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-3-[4-[[(methylsulfonyl)amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-68-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[3-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-70-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-72-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[[[(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-73-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-74-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-75-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-76-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B

RN 677726-77-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[4-[1-[[(5R)-2-oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 677726-78-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-79-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-80-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[4-[1-[[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-81-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-82-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-83-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 677726-84-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-87-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 677726-88-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-89-5 HCAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-90-8 HCAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-77-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-78-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[3-[1-[[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-79-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-80-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-81-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[3-fluoro-4-[(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-82-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-83-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-84-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(2-fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-85-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-86-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(4-fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-87-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(3-hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-88-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-(2-hydroxyethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-89-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-90-1 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-91-2 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-92-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-93-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[2-fluoro-4'-[[(4-quinolinylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-94-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-95-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-[1-[[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-96-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-97-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[2-[1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethoxy]carbonyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-98-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677727-99-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[3-[1-[[(5R)-3-[4-[(dimethylamino)sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-00-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-01-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[[2-[1-[[(5R)-3-cyclopentyl-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-02-8 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-[4-(trifluoromethoxy)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-03-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-[1-[[(5R)-2-oxo-3-[4-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677728-04-0 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(3-fluoro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677729-42-9 HCAPLUS
CN Erythromycin, N-demethyl-N-[2-[1-[[(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 678182-71-3 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-(trans-4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L12 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Feb 2004
GI



AB Antibacterial agents of formula I [A = 2-oxazolidinone, isoxazoline, furanone, etc.; X, Y = CO, (substituted) NH; R = acylamino, heterocyclo, etc.; R1-R3 = H, halo, Me; R4 = H, alkyl, alkoxy, alkylthio, alkylamino] are prepared Thus, II was prepared and had MIC of 1 μg/mL.

ACCESSION NUMBER: 2004:143139 HCAPLUS
DOCUMENT NUMBER: 140:181437
TITLE: Preparation of N-aryl-2-oxazolidinones and their derivatives as antibacterial agents
INVENTOR(S): Gadwood, Robert C.; Ochoada, Jason M.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014897	A1	20040219	WO 2003-US22486	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491287	AA	20040219	CA 2003-2491287	20030801
US 2004072873	A1	20040415	US 2003-632742	20030801
EP 1539745	A1	20050615	EP 2003-784775	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013400	A	20050712	BR 2003-13400	20030801

PRIORITY APPLN. INFO.: US 2002-402783P P 20020812
WO 2003-US22486 W 20030801

OTHER SOURCE(S): MARPAT 140:181437
IT **658073-58-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L12 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryloxazolidinones as antibacterial agents)
RN 658073-58-6 HCAPLUS
CN 2-Piperidinone, 5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 26 Jan 2004
GI



AB Title compds. I [wherein R1 = H, (un)substituted (cyclo)alkyl, (un)substituted alkanoyl, acylmercapto, heterocyclylthiocarbonyl, etc.; R2, R3 = H, halogen; R4 = alkylsulfonyloxy, (un)substituted alkylthiocarbonylamino, (un)substituted ureido, carbamato, etc.; A, B = independently selected from H, alkyl, CO2Et, halogen; and salts or solvates thereof] were prepared as antibacterial agents. For example, reaction of (S)-N-[3-[4-(4-cyanomethylidenepiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]amine with carbon disulfide (69%), followed by addition of sodium methoxide, gave II in 77% yield. II showed 1.56-6.25 μg/mL (MIC) against linezolid resistant strains, such as S. aureus MRSA-32, S. pneumoniae SPN744 and E. faecium 367, 0.2 μg/mL (MIC) against linezolid sensitive strains, such as S. aureus MRSA-32 and S. pneumoniae 49619, 1.56 (MPC) for the treatment of E. faecalis 416 infection, and etc. 3D quant. structure activity relationship (3D-QSAR) showed that the steric contributions of I are over one and half times more than the electrostatic contributions, compared to literature compds. Thus, I and their pharmaceutical compds. targeting multiple ribonucleoprotein sites are useful as antimicrobial agents for treating bacterial infections.

ACCESSION NUMBER: 2004:60503 HCAPLUS
DOCUMENT NUMBER: 140:128407
TITLE: Preparation of (piperidinophenyl)oxazolidinones targeting multiple ribonucleoprotein sites as antibacterial agents
INVENTOR(S): Patel, Mahesh V.; Deshpande, Prasad K.; Sindkhedkar, Milind D.; Gupte, Shrikant V.; Chugh, Yati; Shetty, Nitin; Shukla, Milind C.; Yeole, Ravindra D.; De Souza, Noel J.
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007489	A2	20040122	WO 2003-IN238	20030710
WO 2004007489	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492194	AA	20040122	CA 2003-2492194 20030710
EP 1565461	A2	20050824	EP 2003-753912 20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: US 2002-395164P P 20020711
WO 2003-IN238 W 20030710

OTHER SOURCE(S): MARPAT 140:128407
IT **648918-90-5P 648919-10-2P 648919-12-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)
RN 648918-90-5 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648919-10-2 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 648919-12-4 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **648918-91-6P 648919-11-3P 648920-06-3P**
648920-10-9P 648920-11-0P 648920-33-6P
648920-34-7P 648920-35-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 648918-91-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648919-11-3 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 648920-06-3 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 648920-10-9 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648920-11-0 HCAPLUS
CN 4-Piperidineacetonitrile, 1-[4-[(5R)-5-[(4-cyano-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648920-33-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648920-34-7 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A



IT 648921-31-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)
RN 648921-31-7 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 648921-09-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)
RN 648921-09-9 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648920-35-8 HCAPLUS
CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L12 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Nov 2003
GI



I

AB The title compds. [I; R1-R5 = H, halo, (un)substituted alkoxy; T, Q = halo, OH, NH2, N3, each (un)substituted C1-8 alkoxy, C1-8 alkanoyloxy, C1-8 alkylsulfonyl, C1-8 alkylsulfonyloxy, mono- or di(C1-8 alkyl)amino, C1-8 alkanoylamino, C3-8 cycloalkenylcarbonylamino, monocyclic (un)saturated heterocyclylcarbonylamino, C1-8 alkyloxycarbonylamino, tri(C1-8 alkyl)silyloxy, or N-C1-8 alkyl-N-C1-8 alkyloxycarbonylamino] or pharmacol. acceptable salts thereof or hydrates thereof are prepared These compds. I possess antibacterial activity against sensitive bacteria on which existing drugs are effective as well as multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and Penicillin-resistant Streptococcus pneumoniae (PRSP). Thus, 7.5 μL Et dithioacetate was added to a solution of 15.1 mg 4-[(5S)-5-acetamidomethyl-2-oxooxazolidin-3-yl]-4'-[(5S)-5-aminomethyl-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl (preparation given) in 0.5 mL DMF and stirred at room temperature for 14 h to give 80% 4-[(5S)-5-acetamidomethyl-2-oxooxazolidin-3-yl]-4'-[(5S)-5-thioacetamidomethyl-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl (II). II showed min. inhibitory concentration of 0.125 μg/mL against MRSA and vancomycin-resistant Enterococcus faecium.

ACCESSION NUMBER: 2003:929541 HCAPLUS
DOCUMENT NUMBER: 140:5040
TITLE: Preparation of bis(2-oxooxazolidin-3-yl)biphenyl derivatives as antibacterial agents
INVENTOR(S): Shiokawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Maehashi, Kazunori; Yoshida, Satoshi
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335762	A2	20031128	JP 2002-144414	20020520
PRIORITY APPLN. INFO.:			JP 2002-144414	20020520

OTHER SOURCE(S): MARPAT 140:5040
IT 627542-99-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L12 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Uses)
(prepn. of bisoxooxazolidinyl)biphenyl derivs. as antibacterial agents)
RN 627542-99-8 HCAPLUS
CN Acetamide, N-[[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 627543-24-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bisoxooxazolidinyl)biphenyl derivs. as antibacterial agents)
RN 627543-24-2 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Sep 2003
GI



I II

AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is, for example, halo or (1-4C)alkyl that is substituted by 1 substituent =, for example, OH, (1-4C)alkoxy, amino, cyano, azido; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S) are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compns. containing them are described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 4 and 8 μg/mL, resp. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Sixty-one example prepns. of I are included. For example, to prepare II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (2.7 mmol) (preparation given) was suspended in CH2Cl2 (10 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (4.7 mmol) was added and the reaction mixture was cooled to -5°; diphenylphosphoryl azide (3.25 mmol) was added dropwise and it was stirred for 18 h at room temperature; workup gave 1.02 g of II.

ACCESSION NUMBER: 2003:696895 HCAPLUS
DOCUMENT NUMBER: 139:214459
TITLE: Preparation of 5-azolylmethyl oxazolidinones and their use as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 126 pp.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072576	A2	20030904	WO 2003-GB791	20030225
WO 2003072576	A3	20031231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477379	AA	20030904	CA 2003-2477379	20030225
EP 1480975	A2	20041201	EP 2003-742987	20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008018	A	20050104	BR 2003-8018	20030225
US 2005182112	A1	20050818	US 2003-505902	20030225
JP 2005531504	T2	20051020	JP 2003-571282	20030225
PRIORITY APPLN. INFO.:			US 2002-360688P P	20020228
			WO 2003-GB791 W	20030225

OTHER SOURCE(S): MARPAT 139:214459
IT 591253-17-7P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(methoxycarbonyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-18-8P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-19-9P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-23-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-aminomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-26-8P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-27-9P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-bromomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-30-4P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[(aminoiminomethyl)thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one monohydrobromide 591253-31-5P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(methylthio)methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-34-8P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[(diphenoxyphosphinyl)oxy]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-50-8P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-formyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-54-2P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2,2-dibromoethenyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one 591253-69-9P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-amino-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-75-7P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethoxy-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-77-9P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-bromo-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-84-8P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(2-propynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one
591253-98-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 591254-03-4P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-hydroxyethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-17-7 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-18-8 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(azidomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-19-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-23-5 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-26-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-27-9 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(bromomethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-30-4 HCAPLUS
CN Carbamimidothioic acid, [1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-31-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(methylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-34-8 HCAPLUS
CN Phosphoric acid, [1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-50-8 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-75-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethoxy-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-77-9 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-bromo-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-54-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-69-9 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-amino-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-84-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-propynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-98-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-03-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **591253-16-6P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-cyano-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-20-2P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-21-3P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-trifluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-22-4P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-trifluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-24-6P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(aminocarbonyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-25-7P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[(methoxycarbonyl)amino]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-28-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-32-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(methylsulfonyl)methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
591253-36-0P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-cyanomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-38-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-chloromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-40-6P**, (5R)-3-[4-(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-42-8P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(1H-1,2,3-triazol-4-yl)thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-44-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(1H-imidazol-2-yl)thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-46-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(phenylmethyl)thio]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-48-4P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(dimethylamino)methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-52-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-difluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-56-4P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[2-(3-methyl-5-isoxazolyl)ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-58-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(3-buten-1-ynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-60-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-((E)-2-bromoethenyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-62-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(2-bromoethynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-64-4P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[2-[(ethyl)(methyl)amino]-2-oxoethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-65-5P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[2-(dimethylamino)-2-oxoethyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-67-7P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(ethylaminocarbonyloxy)methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-74-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-acetylamino-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-78-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-chloro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-81-5P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-82-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-83-7P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(3-hydroxy-1-propynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-86-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-87-1P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate **591253-88-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-89-3P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-diethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-90-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-diethylamino-2-butynyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
591253-91-7P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(2,5-dihydro-1H-pyrrol-1-yl)-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-92-8P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(morpholinyl)-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-93-9P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(morpholinyl)-2-butynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one trifluoroacetate **591253-94-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethynyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-96-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxy-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-97-3P**, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591254-00-1P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591254-01-2P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-cyclopropyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591254-04-5P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethenyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591254-05-6P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(methoxymethyl)-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one **591254-06-7P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[5-(methoxymethyl)-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one **591254-07-8P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-chloromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591254-08-9P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethynyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591254-09-0P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591254-10-3P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(2-chloroethyl)-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591254-11-4P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-nitro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-16-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-20-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-21-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-22-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-24-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-32-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(methylsulfonyl)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-36-0 HCAPLUS
CN 1H-1,2,3-Triazole-4-acetonitrile, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-25-7 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-28-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-38-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(chloromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-40-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-42-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(1H-1,2,3-triazol-4-ylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-44-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(1H-imidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-52-0 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(difluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-56-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(3-methyl-5-isoxazolyl)ethynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-46-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[[(phenylmethyl)thio]methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-48-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-58-6 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(3-buten-1-ynyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-60-0 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-[(1E)-2-bromoethenyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-62-2 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(bromoethynyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-64-4 HCAPLUS
CN 1H-1,2,3-Triazole-4-acetamide, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-74-6 HCAPLUS
CN Acetamide, N-[1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-78-0 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-65-5 HCAPLUS
CN 1H-1,2,3-Triazole-4-acetamide, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-67-7 HCAPLUS
CN Carbamic acid, ethyl-, [1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-81-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-82-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-83-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(3-hydroxy-1-propynyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-86-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(4-(dimethylamino)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 591253-88-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-89-3 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-[4-(diethylamino)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-87-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(dimethylamino)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 591253-86-0
CMF C23 H26 F N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 591253-90-6 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-[4-(diethylamino)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 591253-89-3
CMF C25 H30 F N5 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 591253-91-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(2,5-dihydro-1H-pyrrol-1-yl)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-92-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-93-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[4-(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 591253-92-8
CMF C25 H28 F N5 O5 S

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 591253-94-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-96-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxy-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-97-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-00-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(methylthio)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-01-2 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-cyclopropyl-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-04-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethenyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-05-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[4-(methoxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-08-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-09-0 HCAPLUS
CN Carbamic acid, [[1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-06-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[[5-(methoxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-07-8 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(chloromethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591254-10-3 HCAPLUS
CN 2-Oxazolidinone, 5-[[4-(2-chloroethyl)-1H-1,2,3-triazol-1-yl]methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-11-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-nitro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **591253-71-3P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-carboxy-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591253-85-9P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[3-(trimethylsilyl)-2-propynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one **591253-95-1P**, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[2-(trimethylsilyl)ethynyl]-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-71-3 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 591253-85-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[3-(trimethylsilyl)-2-propynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-95-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-[(trimethylsilyl)ethynyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Sep 2003
GI



I



II

AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-methyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is (1-4C)alkyl; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, are useful as antibacterial agents, and processes for their manufacture and pharmaceutical compns. containing them are described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 2 and 4 μg/mL, resp., compared to 2 and 2 μg/mL for the reference compound without the Me substituent. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Fifty-seven example prepns. of intermediates and 44 example prepns. of I are included. For example, to prepare II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-azidomethyloxazolidin-2-one (1.0 mmol; preparation described) was mixed with 5,6,7,8-tetrachloro-2,9-dimethyl-1,4-dihydro-1,4-ethenonaphthalene (2.0 mmol) in dry 1,4-dioxane (4 mL) in a sealed microwave reaction tube. The tube was placed in a Smith microwave reactor at 170° for 20 min. The reaction mixture was then transferred into a round bottom flask and the solvent was removed under vacuum. The residue was purified by chromatog. on silica gel with 5% MeOH in CH_2Cl_2 to give a mixture of the 4- and 5-Me regioisomers. This mixture was further separated on a chiral column (chiralcel OD) with iso-PrOH/hexanes (1:1) to give II (74 mg).

ACCESSION NUMBER: 2003:696894 HCAPLUS
DOCUMENT NUMBER: 139:214458
TITLE: Preparation of 3-cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones and their use as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert; Girardot, Marc Michel
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072575	A1	20030904	WO 2003-GB785	20030225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477344	AA	20030904	CA 2003-2477344	20030225
BR 2003008056	A	20041207	BR 2003-8056	20030225
EP 1497286	A1	20050119	EP 2003-704812	20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119292	A1	20050602	US 2003-506020	20030225
JP 2005524661	T2	20050818	JP 2003-571281	20030225
NO 2004003950	A	20041013	NO 2004-3950	20040921
PRIORITY APPLN. INFO.:			US 2002-360957P	P 20020228
			WO 2003-GB785	W 20030225

OTHER SOURCE(S): MARPAT 139:214458

IT **591232-01-8P**, (5R)-3-[3-Fluoro-4-(1-oxo-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-62-1P**, (5R)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-91-6P**, (5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-96-1P**, (5R)-3-[4-[1-(Acetoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-01-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-62-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-91-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-96-1 HCAPLUS
CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591231-77-5P, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-84-4P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-isopropyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-90-2P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

one 591231-95-7P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-butyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-97-9P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-00-7P, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-02-9P, (5R)-3-[4-(1,1-Dioxo-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-03-0P, (5R)-3-[3,5-Difluoro-4-(1-oxo-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-09-6P, (5R)-3-[4-(1,1-Dioxo-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-11-0P, (5R)-3-[4-(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-12-1P, (5R)-3-[4-(1,1-Dioxo-2,5-dihydrothien-3-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-13-2P, (5R)-3-[3-Fluoro-4-(4-bromo-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-15-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-23-4P, (5R)-3-[3-Fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-31-4P, (5R)-3-[3-Fluoro-4-[4-[(hydroxyimino)methyl]imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-42-7P, (5R)-3-[3-Fluoro-4-[4-formylimidazol-1-yl]phenyl]-5-[(4-pentyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-43-8P, (5R)-3-[3-Fluoro-4-[4-(hydroxymethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-46-1P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-49-4P, (5R)-3-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-50-7P, (5R)-3-[3-Fluoro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-58-5P, (5R)-3-[3-Fluoro-4-(trans-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-60-9P, (5R)-3-[3-Fluoro-4-(cis-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 591232-68-7P, (5R)-3-[4-(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-69-8P, (5R)-3-[3,5-Difluoro-4-(trans-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-70-1P, (5R)-3-[3,5-Difluoro-4-(cis-1-oxotetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-88-1P, (5R)-3-[3,5-Difluoro-4-(1-glycoloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-93-6P, (5R)-3-[4-[1-((2S)-2,3-Dihydroxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-95-0P, (5R)-3-[3-Fluoro-4-(1-glycoloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591231-77-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 591231-84-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[[4-(1-methylethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591231-90-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591231-95-7 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591231-97-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-03-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-09-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-00-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-02-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-11-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-12-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(2,5-dihydro-1,1-dioxido-3-thienyl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-13-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-15-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-23-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-46-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-49-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-50-7 HCAPLUS
CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-31-4 HCAPLUS
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 591232-42-7 HCAPLUS
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-[(4-pentyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-43-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(hydroxymethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-58-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-60-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-68-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-69-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-93-8 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-95-0 HCAPLUS
CN Pyridine, 4-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591232-70-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-88-1 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 591232-98-3P, (5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)
RN 591232-98-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-98-6P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 501940-28-9P,

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **591232-44-9P**, (5R)-3-[4-[4-[(tert-Butyldimethylsilyloxy)methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-89-2P**, (5R)-3-[4-(1-Acetoxyacetyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-90-5P**, (5R)-3-[3,5-Difluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one hydrochloride **591232-94-9P**, (5R)-3-[4-[1-[((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one **591232-97-2P**, (5R)-3-[3-Fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one monohydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 501939-98-6 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-28-9 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● x HCl

RN 591232-94-9 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-97-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 591232-44-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-89-2 HCAPLUS
CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2,6-difluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-90-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, hydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

IT **591231-82-2P**, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591231-82-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Jul 2003
GI



AB Title compds. I (R1 = H, halo, alkyl, or haloalkyl; R2 = morpholinyl, piperidinyl or its derivative, or 4-substituted piperazinyl; R3 = OH, SH, acyloxy, sulfonyloxy, acylamino, diacylimino, pentabasic heterocyclic group or its derivs.; and when R1 = F, R2 or R3 = morpholinyl or acetamido), useful as antibacterial agents against Gram-pos. bacteria, are prepared For example, (R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone was converted to mesylate, condensed with potassium phthalimide , and treated with aqueous MeNH2 to give the bactericide linezolid.

ACCESSION NUMBER: 2003:576097 HCAPLUS
DOCUMENT NUMBER: 139:85332
TITLE: Preparation of oxazolidone derivatives as antibacterial agents
INVENTOR(S): Liu, Jun; Meng, Qingguo; Jin, Jie; Wu, Yanbin
PATENT ASSIGNEE(S): Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 50 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1355165	A	20020626	CN 2001-144613	20011219
PRIORITY APPLN. INFO.:			CN 2001-144613	20011219

OTHER SOURCE(S): CASREACT 139:85332; MARPAT 139:85332
IT 556801-07-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidone derivs. as antibacterial agents)
RN 556801-07-1 HCAPLUS
CN 2-Oxazolidinone, 5-(1H-benzotriazol-1-ylmethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jun 2003
AB PH-027 is a new 5-triazole oxazolidinone synthesized that shows strong activity against Gram-pos. aerobic bacteria, including clin. isolates. The objective of this study was to investigate the in vitro activity of this compound in comparison with linezolid and other antibiotics against Gram-pos. and Gram-neg. anaerobes. The in vitro activity of PH-027 in comparison with those of linezolid and other antimicrobial agents was evaluated against 201 clin. isolates of Gram-pos. and Gram-neg. anaerobic bacteria by agar dilution and Etest methods. PH-027 showed excellent activity, with min. inhibitory concns. (MIC) in the range of 0.12-4.0 μg/mL against all isolates; MIC90s being 4.0, 1.0, 2.0, 2.0 and 2.0 μg/mL against Clostridium difficile, Peptostreptococcus spp., Bacteroides fragilis, Prevotella bivia and Fusobacterium spp. resp. In comparison, linezolid had MIC in the range of 0.5-4.0 μg/mL against all isolates, with MIC90s of 2.0, 4.0, 4.0, 4.0 and 2.0 μg/mL against the same set of bacteria resp. PH-027 demonstrated excellent in vitro activity that is superior to linezolid against Peptostreptococcus spp., B. fragilis and P. bivia. However, against C. difficile and Fusobacterium spp, PH-027 and linezolid showed comparable in vitro activity. Against all anaerobes, metronidazole, PH-027 and, to a lesser extent, linezolid had the most potent activity. From the results of in vitro susceptibility testing, both linezolid and PH-027 show promise in the treatment of anaerobic infections.

ACCESSION NUMBER: 2003:471767 HCAPLUS
DOCUMENT NUMBER: 139:49714
TITLE: Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria
AUTHOR(S): Phillips, O. A.; Rotimi, V. O.; Jamal, W. Y.; Shahin, M.; Verghese, T. L.
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait
SOURCE: Journal of Chemotherapy (Firenze, Italy) (2003), 15(2), 113-117
CODEN: JCHEEU; ISSN: 1120-009X
PUBLISHER: E.I.F.T. srl
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 503090-32-2, PH 027
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(comparative in vitro activity of PH-027 vs. other antimicrobials against clin. isolates of Clostridium difficile and other anaerobic bacteria)
RN 503090-32-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Jun 2003
GI



I

AB Title compds. [I; R1 = H, NR5R6, CR7R8R9, CR2OR14, CH2NHR14, COR13, C(:NOH)H, C(:NOR13)H, C(:NOH)R13, C(:NOH)R13, CON(R13)2, C(:NOH)N(R13)2, NHC(:X1)N(R13)2, (C:NH)R7, N(R13)C(:X1)N(R13)2, CO2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyanoalkyl, CN, CH:C(R)2, OH, COCHR13, C(:NR13)R13, NHC(:X1)R13, (substituted) heterocycle; Ar = (substituted) aryl, heteroaryl, heterocyclyl; R3 = NR13(C:X2)R12, NR13(C:X1)R12, NR13SO2R14, NR13(CHR13)0-4aryl, NR13(CHR13)0-4heteroaryl, S(CHR3)0-4aryl, S(CHR13)0-4heteroaryl, O(CHR13)0-4aryl, O(CHR13)0-4heteroaryl; OCR13:NR16, (substituted) heterocyclyl; R5, R6 = H, (substituted) alkyl, acyl, heterocyclyl; R5R6 = atoms to form 3-7 membered heterocyclyl; R7 = H, halo, OH, alkoxy, alkyl, alkenyl, (substituted) amino; R8, R8 = H, cyano, (substituted) alkyl, Ph; R7R8 = atoms to form a 3-7 membered (heterocyclyl) ring; X1 = O, S, NR13, NCN, NSO2R14; R13 = H, alkyl, NR5R6, SR8, OH, cyano, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocyclyl, Ph], were prepared Thus, N-[5(S)-3-[4-(1-cyanocyclopropan-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (preparation given) in PhMe was treated with Lawesson's reagent and stirred at 80° for 2 h to give N-[5(S)-3-[4-(1-cyanocyclopropan-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]thioacetamide. The latter inhibited Staphylococcus aureus Smith with a min. inhibitory concentration of 0.125 μg/mL.

ACCESSION NUMBER: 2003:454302 HCAPLUS
DOCUMENT NUMBER: 139:36518
TITLE: Preparation of chiral cyclopropylphenyloxazolidinones as antibiotics
INVENTOR(S): Fukuda, Yasumichi
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048136	A1	20030612	WO 2002-US38153	20021127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
XG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2463794	AA	20030612	CA 2002-2463794	20021127
US 2003225107	A1	20031204	US 2002-305368	20021127
US 6686363	B2	20040203		
EP 1448536	A1	20040825	EP 2002-797154	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005511688	T2	20050428	JP 2003-549328	20021127

PRIORITY APPLN. INFO.: US 2001-333741P P 20011129
WO 2002-US38153 W 20021127

OTHER SOURCE(S): MARPAT 139:36518

IT **543682-63-9P 543682-75-3P 543682-78-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of chiral cyclopropylphenyloxazolidinones as antibiotics)

RN 543682-63-9 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-75-3 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-(azidomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-78-6 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-[[(methylsulfonyl)oxy]methyl]-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **543682-51-5P 543682-52-6P 543682-53-7P**
543682-54-8P 543682-55-9P 543682-64-0P
543682-65-1P 543682-66-2P 543682-67-3P
543682-68-4P 543682-69-5P 543682-70-8P
543682-71-9P 543682-72-0P 543682-73-1P
543682-74-2P 543682-76-4P 543682-77-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of chiral cyclopropylphenyloxazolidinones as antibiotics)

RN 543682-51-5 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-52-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 5-amino-1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-53-7 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 543682-54-8 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-55-9 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-64-0 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-65-1 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-66-2 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-67-3 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-68-4 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-69-5 HCAPLUS

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-1,2,3-Triazole-4-carboxamide, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-70-8 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-formyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-71-9 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-[(hydroxyimino)methyl]-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-72-0 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-73-1 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-[(methoxyimino)methyl]-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-77-5 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 543683-57-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of chiral cyclopropylphenyloxazolidinones as antibiotics)
RN 543683-57-4 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[2-methyl-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-74-2 HCAPLUS
CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[[4-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-76-4 HCAPLUS
CN Acetamide, N-[[1-[[(5R)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 May 2003
GI



AB Title compds. I [wherein HET = (un)substituted N-linked 5-membered heterocyclic or 6-membered dihydroheteroaryl ring containing heteroatoms selected from N, O, and S; Q = Q1, Q2, etc.; R2 and R3 = independently H or F; T = (un)substituted C-linked 5-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; preferably T = (un)substituted 1,3,4-thiadiazolyl, thiazolyl, 1,3,4-oxadiazolyl, or oxazolyl; and pharmaceutically acceptable salts or hydrolyzable esters thereof] were prepared as antibacterial agents. For example, (5R)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one was mesylated and the product converted to the azide. Cyclization of the azide with bicyclo[2.2.1]heptadiene gave the 1,2,3-triazole, which was substituted with hexamethylditin to afford the stannane. Reaction with 5-chloro-1,3,4-thiadiazole-2-carbonitrile in the presence of AsPh3 and tris(dibenzylidenenacetone)dipalladium in N-methyl-2-pyrrolidinone provided II. The latter inhibited bacterial growth against Staphylococcus aureus (methicillin sensitive and quinolone sensitive), Staphylococcus aureus (methicillin resistant and quinolone resistant), Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis with MIC values of 0.125 μg/mL, 0.25 μg/mL, 0.125 μg/mL, 0.125 μg/mL, 2 μg/mL, and 0.5 μg/mL, resp.

ACCESSION NUMBER: 2003:335104 HCAPLUS
DOCUMENT NUMBER: 138:353972
TITLE: Preparation of 3-aryloxazolidinones with antibacterial activity
INVENTOR(S): Gravestock, Michael Barry
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035648	A1	20030501	WO 2002-GB4796	20021023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2396350	A1	20040623	GB 2004-8399	20021023
EP 1446403	A1	20040818	EP 2002-770098	20021023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005519870	T2	20050707	JP 2003-538164	20021023
US 2005043374	A1	20050224	US 2004-493609	20041018
PRIORITY APPLN. INFO.:			US 2001-330589P	P 20011025
			WO 2002-GB4796	W 20021023

OTHER SOURCE(S): MARPAT 138:353972
IT 519003-00-0P, (5R)-3-[3-Fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-02-2P, (5R)-3-[3-Fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-03-3P, (5R)-3-[4-[5-(Aminomethyl)-1,3-thiazol-2-yl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-05-5P, (5R)-3-[3-Fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-11-3P, (5R)-3-[3-Fluoro-4-(4-methyl-1,3-thiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-14-6P, (5R)-3-[3-Fluoro-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-16-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of (aryl)oxazolidinones as antibacterial agents)
RN 519003-00-0 HCAPLUS
CN 1,3,4-Thiadiazole-2-carbonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 519003-02-2 HCAPLUS
CN 1,3,4-Thiadiazole-2-carboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-03-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-(aminomethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-05-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 519003-11-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-14-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(trifluoromethyl)-2-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-16-8 HCAPLUS
CN 1,3,4-Thiadiazole-2-acetonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **501939-94-2P**, (5R)-3-[3-Fluoro-4-(trimethylstannyl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501939-95-3P**, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **519003-06-6P**, 2-Fluoro-N'-acetyl-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-3-yl]benzohydrazide **519003-07-7P** **519003-08-8P** **519003-12-4P** **519003-13-5P** **519003-15-7P** **519003-17-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (aryl)oxazolidinones as antibacterial agents)

RN 501939-94-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 519003-08-8 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-12-4 HCAPLUS
CN Benzenecarbothioamide, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-13-5 HCAPLUS
CN Benzamide, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 519003-06-6 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 2-acetylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-07-7 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-15-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-17-9 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 2-(cyanoacetyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Mar 2003
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones and isoxazolines (shown as I; variables defined below; e.g. (5S,5S')-N-[3-[4'-[5-(acetylaminomethyl)-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-ylmethyl]acetamide (shown as II)), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manufacture and pharmaceutical compns. containing them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(:W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 μg/mL, resp. Prepns. of 64 examples of I and many intermediates are included. For example, I was prepared as follows: (5S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methyl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixture of DMF (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N. Pd(II) acetate (0.04 mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated.

ACCESSION NUMBER: 2003:221667 HCAPLUS
DOCUMENT NUMBER: 138:238171
TITLE: Preparation of oxazolidinones and/or isoxazolines as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030320	WO 2002-GB4120	20020909

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	B1	20050713		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002012458	A	20041019	BR 2002-12458	20020909
JP 2005507386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 531621	A	20050624	NZ 2002-531621	20020909
AT 299502	E	20050715	AT 2002-765019	20020909
ZA 2004001888	A	20050418	ZA 2004-1888	20040308
NO 2004001428	A	20040608	NO 2004-1428	20040405
PRIORITY APPLN. INFO.:			GB 2001-21942	A 20010911
			GB 2002-15420	A 20020704
			WO 2002-GB4120	W 20020909

OTHER SOURCE(S): MARPAT 138:238171

IT 501940-31-4P, (5R)-5-[[(tert-Butyldimethylsilyl)oxy]methyl]-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-39-2P, (5R)-3-[4'-[5-[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-43-8P, (5R)-3-[4'-[5-[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501940-31-4 HCAPLUS
CN 2-Oxazolidinone, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-39-2 HCAPLUS

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-43-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-93-1P, (5R,5'R)-4,4'-Bis[5-(1H-1,2,3-triazol-1-yl)methyl-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl 501939-96-4P, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-04-1P, N-[[3-[2,2'-Difluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl]acetamide 501940-11-0P, (5R)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-12-1P, (5R)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-26-7P, (5R,5'R)-3-[2,2'-Difluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-29-0P**, (5R)-5-(Hydroxymethyl)-3-[4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one **501940-33-6P 501940-37-0P**, (5R)-3-[2-Fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-38-1P**, (5R)-5-(Hydroxymethyl)-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one **501940-41-6P**, (5R)-5-(1H-1,2,3-Triazol-1-ylmethyl)-3-[4'-[5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one **501940-42-7P**, (5R)-3-[2-Fluoro-4'-[5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-46-1P**, (5R)-3-[4'-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-48-3P**, (5R)-3-[4'-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-59-6P**, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-74-5P**, (5R)-3-[4-[5-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-76-7P**, (5R)-3-[4-[5-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-78-9P**, (5R)-3-[3-Fluoro-4-[5-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-79-0P**, (5R)-3-[3-Fluoro-4-[5-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-83-6P**, (5R)-3-[5-[5-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]pyrid-2-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one **501940-84-7P**, (5R)-3-[5-[5-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]thien-2-yl]pyrid-2-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-86-9P**, (5R)-3-[3-Fluoro-4-[2-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyrid-5-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one **501940-91-6P**, (5R)-3-[3-Fluoro-4-[6-(5-hydroxymethyl-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-93-1 HCAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501939-96-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-04-1 HCAPLUS
CN Acetamide, N-[[3-[2,2'-difluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro-5-isoxazolyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-11-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-12-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 501940-26-7 HCAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-29-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-33-6 HCAPLUS
CN 2-Oxazolidinone, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2'-fluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-37-0 HCAPLUS
CN 2-Oxazolidinone, 3-[2-fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-38-1 HCAPLUS
CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-41-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-42-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-46-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-48-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 501940-59-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-74-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-76-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 501940-78-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-79-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-83-6 HCAPLUS
CN 2-Oxazolidinone, 3-[5-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-2-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-84-7 HCAPLUS

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[5-[5-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-thienyl]-2-pyridinyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-86-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-91-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-95-3, (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501939-97-5, (5R)-3-[4'-[5-[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-97-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 501939-67-9P, (5R)-3-(5-Bromopyrid-2-yl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501939-69-1P, (5R)-3-(5-Bromopyrid-2-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-70-4P, (5R)-3-(4-Iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501939-73-7P, (5R)-3-(4-Iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-94-2P, (5R)-3-[3-Fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501939-98-6P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-19-8P, (5R)-3-[4'-[5-[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-20-1P, (5R)-3-[4'-[5-[[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-27-8P, (5R)-3-[3-Fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-28-9P, (5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
RN 501939-67-9 HCAPLUS
CN 2-Oxazolidinone, 3-(5-bromo-2-pyridinyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 501939-69-1 HCAPLUS
CN 2-Oxazolidinone, 3-(5-bromo-2-pyridinyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-70-4 HCAPLUS
CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-73-7 HCAPLUS
CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501939-94-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-98-6 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 501940-19-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-20-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-27-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-28-9 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 Dec 2002
AB A series of 5-substituted oxazolidinones with varying substitution at the 5-position of the oxazolidinone ring were synthesized and their in vitro antibacterial activity was evaluated. The compds. demonstrated potent to weak antibacterial activity. A novel compound (PH-027) demonstrated potent antibacterial activity, which is comparable to or better than those of linezolid and vancomycin against antibiotic-susceptible standard and clin. isolated resistant strains of gram-pos. bacteria. Although the presence of the C-5-acetamidomethyl functionality at the C-5 position of the oxazolidinones has been widely claimed and reported as a structural requirement for optimal antimicrobial activity in the oxazolidinone class of compds., our results from this work identified the C-5 triazole substitution as a new structural alternative for potent antibacterial activity in the oxazolidinone class.
ACCESSION NUMBER: 2002:915641 HCAPLUS
DOCUMENT NUMBER: 138:268234
TITLE: Synthesis and antibacterial activity of 5-substituted oxazolidinones
AUTHOR(S): Phillips, O. A.; Udo, E. E.; Ali, A. A. M.; Al-Hassawi, N.
CORPORATE SOURCE: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kuwait University, Safat, 13110, Kuwait
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(1), 35-41
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:268234
IT **503026-25-3P**
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antibacterial activity of 5-substituted oxazolidinones)
RN 503026-25-3 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antibacterial activity of 5-substituted oxazolidinones)
RN 503026-26-4 HCAPLUS
CN 2-Oxazolidinone, 5-[(5-acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **503026-28-6P 503026-29-7P**
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and antibacterial activity of 5-substituted oxazolidinones)
RN 503026-28-6 HCAPLUS
CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT **503026-27-5P 503090-32-2P**, PH 027
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antibacterial activity of 5-substituted oxazolidinones)
RN 503026-27-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[1-(methoxyimino)ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 503090-32-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **503026-26-4P**

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 503026-29-7 HCAPLUS
CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 Na

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 18 Oct 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; HET = N-linked 5-membered, fully or partially unsatd. heterocyclic ring, or an N-linked 6-membered di-hydro-heteroaryl ring; Q = II, III, etc. (wherein R2, R3 = H, F; T = IV, V, etc.)] and their pharmaceutically-acceptable salts, useful in production of an antibacterial effect in a warm blooded animal, were prepared E.g., detailed multi-step synthesis of (5R)-VI as its mesitylene sulfonate salt, starting from 3,5-difluoroaniline and tetrahydrothiopyran-4-one, was described. Antibacterial properties of compound VI were tested against 5 different bacteria, and its MIC values were given.

ACCESSION NUMBER: 2002:793623 HCAPLUS
DOCUMENT NUMBER: 137:310923
TITLE: Preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics
INVENTOR(S): Betts, Michael John; Swain, Michael Lingard; Hales, Neil James; Huynh, Hoan Khai
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002081470	A1	20021017	WO 2002-GB1644		20020403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1385844	A1	20040204	EP 2002-720195		20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004531518	T2	20041014	JP 2002-579458		20020403
US 2005032861	A1	20050210	US 2004-480959		20040628
PRIORITY APPLN. INFO.:			GB 2001-8765	A	20010407
			US 2001-330588P	P	20011025
			WO 2002-GB1644	W	20020403

OTHER SOURCE(S): MARPAT 137:310923
IT **471913-40-3P 471913-42-5P 471913-43-6P 471913-46-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of oxazolidinones substituted by novel sulfilimine and sulfoximine-contg. rings as antibiotics)

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 471913-40-3 HCAPLUS
CN 2H-Thiopyran, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-42-5 HCAPLUS
CN Benzenesulfonic acid, 2,4,6-trimethyl-, compd. with (5R)-3-[4-(1,1,3,6-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-2-oxazolidinone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 471913-41-4
CMF C17 H17 F2 N5 O3 S

Absolute stereochemistry.



L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 3453-83-6
CMF C9 H12 O3 S



RN 471913-43-6 HCAPLUS
CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-46-9 HCAPLUS
CN Thiomorpholine, 1-[[(cyanoimino)(methylthio)methyl]imino]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 471913-44-7P 471913-45-8P 471913-47-0P
471913-48-1P 471913-49-2P 471913-50-5P
471913-51-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics)

RN 471913-44-7 HCAPLUS
CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-(methylimino)-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 471913-45-8 HCAPLUS
CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-[(1H-imidazol-2-ylmethyl)imino]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-47-0 HCAPLUS
CN Thiomorpholine, 1-[[(cyanoimino)(dimethylamino)methyl]imino]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 471913-48-1 HCAPLUS
CN Thiomorpholine, 1-[[4-amino-5-(methoxycarbonyl)-2-thiazolyl]imino]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-49-2 HCAPLUS
CN 2H-Thiopyran, 1-(acetylimino)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-50-5 HCAPLUS
CN 2H-Thiopyran, 1-(acetylimino)-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-51-6 HCAPLUS
CN 2H-Thiopyran, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-1-[(hydroxyacetyl)imino]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 371195-00-5P 371195-01-6P 371195-03-8P
371195-04-9P 471913-52-7P 471913-53-8P
471913-54-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics)

RN 371195-00-5 HCAPLUS

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-01-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-03-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 471913-53-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-54-9 HCAPLUS
CN 2H-Thiopyran, 1-[[(acetyloxy)acetyl]imino]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-04-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-52-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Nov 2001
GI



AB The title compds. [I; X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heteroaryl ring containing 2-4 heteroatoms selected from N, O and S, etc.; Q = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsatd.) 5-membered heteroaryl ring system or IV; Rc = R13CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.)], useful as antibacterial agents, were prepared and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 μg/mL against Staphylococcus aureus (Oxford), was given.

ACCESSION NUMBER: 2001:798227 HCAPLUS
DOCUMENT NUMBER: 135:344473
TITLE: Oxazolidinone derivatives with antibacterial activity
INVENTOR(S): Gravestock, Michael Barry; Betts, Michael John; Griffin, David Alan; Matthews, Ian Richard
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081350	A1	20011101	WO 2001-GB1815	20010423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405349	AA	20011101	CA 2001-2405349	20010423
BR 2001010240	A	20030107	BR 2001-10240	20010423
EP 1286998	A1	20030305	EP 2001-921669	20010423
EP 1286998	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531211	T2	20031021	JP 2001-578439	20010423
EE 200200598	A	20040415	EE 2002-598	20010423
NZ 521765	A	20040528	NZ 2001-521765	20010423
AT 268778	E	20040615	AT 2001-921669	20010423
PT 1286998	T	20040930	PT 2001-921669	20010423
ES 2220759	T3	20041216	ES 2001-1921669	20010423
AU 781784	B2	20050616	AU 2001-48636	20010423
ZA 2002008187	A	20040211	ZA 2002-8187	20021010
NO 2002005091	A	20021209	NO 2002-5091	20021023
US 2003216373	A1	20031120	US 2003-258355	20030506
HK 1053114	A1	20050218	HK 2003-105394	20030725

PRIORITY APPLN. INFO.: GB 2000-9803 A 20000425
WO 2001-GB1815 W 20010423

OTHER SOURCE(S): MARPAT 135:344473

IT **371194-18-2P 371194-19-3P 371194-20-6P**
371194-23-9P 371194-26-2P 371194-34-2P
371194-35-3P 371194-37-5P 371194-39-7P
371194-42-2P 371194-57-9P 371194-63-7P
371194-67-1P 371194-69-3P 371194-71-7P
371194-73-9P 371194-75-1P 371195-01-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(oxazolidinone derivs. with antibacterial activity)

RN 371194-18-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-19-3 HCAPLUS
CN 4-Piperidinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-20-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4-amino-1-piperidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-23-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-26-2 HCAPLUS
CN Acetamide, 2-(acetyloxy)-N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-34-2 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-35-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-37-5 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-39-7 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-67-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 371194-69-3 HCAPLUS
CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-42-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(3S)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 371194-57-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(methylthio)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-63-7 HCAPLUS

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-71-7 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-73-9 HCAPLUS
CN Pyridine, 1-[(acetyloxy)acetyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-75-1 HCAPLUS
CN Pyridine, 1-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-01-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 371194-21-7P 371194-22-8P 371194-24-0P
371194-25-1P 371194-27-3P 371194-28-4P
371194-29-5P 371194-30-8P 371194-31-9P
371194-32-0P 371194-33-1P 371194-36-4P
371194-38-6P 371194-40-0P 371194-41-1P
371194-43-3P 371194-44-4P 371194-45-5P
371194-46-6P 371194-58-0P 371194-59-1P
371194-62-6P 371194-64-8P 371194-65-9P
371194-66-0P 371194-68-2P 371194-70-6P
371194-72-8P 371194-74-0P 371194-76-2P
371194-94-4P 371194-95-5P 371194-96-6P
371194-97-7P 371194-98-8P 371194-99-9P
371195-00-5P 371195-02-7P 371195-03-8P
371195-04-9P 371195-17-4P 371195-18-5P
371195-19-6P 371195-20-9P 371195-21-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxazolidinone derivs. with antibacterial activity)
RN 371194-21-7 HCAPLUS
CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-22-8 HCAPLUS
CN Carbamic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-24-0 HCAPLUS
CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-25-1 HCAPLUS
CN Carbamic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-27-3 HCAPLUS
CN Acetamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-28-4 HCAPLUS
CN Piperazine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-29-5 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolidinyl]phenyl]-4-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-30-8 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-hydroxyethyl)methylamino]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-31-9 HCAPLUS
CN Acetamide, N-[2-[[2-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl]amino]ethyl]-

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-32-0 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-methoxyethyl)methylamino]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-33-1 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-methoxyethyl)amino]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-36-4 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-38-6 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, (2S)-2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-40-0 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-41-1 HCAPLUS
CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-43-3 HCAPLUS
CN Acetamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-44-4 HCAPLUS
CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 371194-45-5 HCAPLUS
CN Methanesulfonamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-46-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-58-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(methylsulfonyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-59-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(1,1-dimethylethyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-62-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-64-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-65-9 HCAPLUS
CN 1(2H)-Pyridinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-66-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-68-2 HCAPLUS
CN 1(2H)-Pyridinecarboxaldehyde, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-74-0 HCAPLUS
CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-76-2 HCAPLUS
CN Pyridine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-70-6 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-72-8 HCAPLUS
CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-94-4 HCAPLUS
CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-95-5 HCAPLUS
CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-96-6 HCAPLUS
CN Pyridine, 1-(ethylsulfonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-97-7 HCAPLUS
CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-00-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-02-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-98-8 HCAPLUS
CN Pyridine, 1-[(3-chloropropyl)sulfonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-99-9 HCAPLUS
CN Pyridine, 4-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(2-methoxyethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-03-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-04-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-17-4 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(4-morpholinylacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-18-5 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-hydroxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-21-0 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-methoxyethyl)amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 371196-57-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxazolidinone derivs. with antibacterial activity)
RN 371196-57-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-19-6 HCAPLUS
CN Acetamide, N-[2-[[2-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-20-9 HCAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[[(2-methoxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 371195-29-8P 371195-30-1P 371195-31-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxazolidinone derivs. with antibacterial activity)
RN 371195-29-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-30-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-31-2 HCAPLUS
CN Piperazine, 1-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L12 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Aug 1989
GI



AB The synthesis and structure/activity studies of the effect of varying the B group in a series of oxazolidinone antibacterials I (R = Me2CH, Me, SO2, Ac, etc.; R1 = B = H, Me, OH, NHAc, etc.) are described. Two synthetic routes were used (1) alkylation of aniline with glycidol followed by dialkyl carbonate heterocyclization to afford I (R = H, R1 .tplbond. B = OH), whose arene ring was further elaborated by using electrophilic aromatic substitution methodol.; (2) cycloaddn. of substituted aryl isocyanates with epoxides. I with B = OH or Br were converted to other B functionalities by using SN2 methodol. Antibacterial evaluation of compds. I with R = acetyl, iso-Pr, methylthio, methylsulfinyl, methylsulfonyl, and sulfonamido and a variety of different β groups against Staphylococcus aureus and Enterococcus faecalis concluded that the compds. with B = aminoacyl, and particularly acetamido, were the most active of those examined in each R series, possessing MIC's in the range of 0.5-4 μg/mL for the most active compds. described.

ACCESSION NUMBER: 1989:457600 HCAPLUS
DOCUMENT NUMBER: 111:57600
TITLE: Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The B group
AUTHOR(S): Gregory, Walter A.; Brittelli, David R.; Wang, C. L. J.; Wuonola, Mark A.; McRipley, Ronald J.; Eustice, David C.; Eberly, Virginia S.; Slee, Andrew M.; Forbes, Martin; Bartholomew, P. T.
CORPORATE SOURCE: Exp. Stn., E. I. du Pont de Nemours and Co., Wilmington, DE, 19898, USA
SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1673-81 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:57600
IT 121372-95-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 121372-95-0 HCAPLUS
CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[[3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-, dimethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.